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Abstract 
Some of the most exciting questions in chemistry lay within the realm of molecular 
biology. Although different disciplines, throughout history we see chemists and chemical 
techniques leading the way in important biological discoveries. Metabolomics is a new, 
developing technique in molecular biology that is spurred on by technical innovations, primarily 
from the chemistry and engineering fields. Here, two different liquid chromatography mass 
spectrometry techniques and state-of-the-art bioinformatic tools are employed to help expand the 
field of metabolomics. In the application phase of this project, metabolomic techniques were 
applied in a multiomic experiment to elucidate the metabolic pathways used in Staphylococcus. 
Multi-omics are the coupling of multiple omics techniques such as metabolomics, genomics, and 
proteomics. In particular, an Ultra-Performance Liquid Chromatography-High Resolution Mass 
Spectrometry platform was used with a semi-targeted metabolomics technique. Large fold-
changes are observed in metabolites mevalonate and phosphomevalonate, which are important 
distinguishing metabolites between the two isoprenoid synthesis routes. This is used to 
characterize isolates based on which metabolic pathway they use. This is further verified and 
expanded by the use of comparative genomics. In the developmental phase of this project, 
metabolomics techniques were advanced by testing and comparing different extraction methods 
for multiomic analyses. In this case, chloroform-based extractions were tested against methyl-
tert-butyl ether-based extractions to collect metabolites, lipids, and proteins simultaneously. This 
was analyzed using a High-Performance Liquid Chromatography-High Resolution Mass 
Spectrometry platform with split-flow nano chromatography and electrospray ionization. 
Additionally, the cell lysis method is investigated to determine its impact on extraction efficiency 
and metabolite degradation. Optimizing extraction procedures will make multi-omics faster, 
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What is metabolomics? What questions does it seek to answer? Why would a 
bioanalytical chemist be interested in it? To answer these questions, we must first start at a 
surprising place, the Human Genome Project (HGP, https://www.genome.gov/human-genome-
project). The genomics revolution was driven by technological advancements that allowed 
genomes to be rapidly and accurately sequenced. With the completion of the HGP and the 
sequencing of the human genome, many people thought vast numbers of diseases would be 
explained and rapidly cured. Despite expectations, however, there have been relatively few 
improvements to modern medicine. Those who had high hopes for the HGP underestimated 
several factors. 
First, despite dramatic improvements and the maturation of genomics as a field, there are 
still technical hurtles that can be challenging to genomics studies. Larger eukaryotic genomes are 
known to have large stretches of highly repetitive sequences in chromosomes such as satellites. 
These can make full sequencing problematic, as it is difficult to stitch together contigs when the 
separating sequences are extremely large. Indeed, if there is too much repetition of any kind 
(such as polyploidy common in plants), the technical and informatic burden become great, and 
sequences are often prohibitively difficult to assemble. 
The second limitation of genomics is that it is not yet possible to unambiguously explain 
gene function from sequence alone, at least not ab initio. One difficulty in explaining function is 
that the DNA sequence does not directly relate to amino acid sequence. This is the case because 
after transcription to mRNA, introns (non-amino acid coding sections of the gene) are removed 
and the exons (coding sections) are stitched back together. This changes the final sequence from 
what one would expect by analyzing the gene sequence alone. Finally, protein folding and post-
translational modifications also must be taken into account which add a further confounding 
layer of complexity. When it comes to protein biochemistry, structure is critical to determine 
function. Without knowing how the polypeptide will fold and wrap together, it is challenging to 
elucidate the function from the sequence alone. 
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Thirdly, there are a vast number of different regulatory mechanisms governing post-
translation modifications (PTM), as well as which genes are active. Transcriptional regulation is 
a complex process that determines which genes are transcribed into mRNA to code for proteins. 
Many genes are only activated in response to certain stimuli, and from the genetic sequence, it is 
impossible to know which genes are active when. Furthermore, after being translated, many 
modifications can occur. For example, for collagen to form its functional trimeric form, many 
PTMs must occur, including PTMs like glycosylation and hydroxylation (a process involving at 
least nine enzymes).1 The failure of this process leads to the disease known as scurvy. This is not 
an isolated event, many different PTMs occur regularly in biological systems including: 
phosphorylation, methylation, glycosylation, and acylation, among others.2 This complexity 
again separates protein function from genetic code, making a complete and dynamic biological 
interpretation impossible. 
Finally, a simplistic genomics view of physiology fails to account for the role of 
environmental factors feeding into this network of regulatory and signaling pathways. This can 
occur at many levels through epigenetics, hormone signaling, and metabolic inputs. One must 
dig deeper to get an understanding of the biological state of an organism. Instead of merely 
sequencing the genome, in order to get more direct biological information, many attempt to 
interrogate which proteins exist at what concentrations. This is the field of proteomics. 
 
Proteomics 
Proteomics involves the global analysis of all proteins in a cell, tissue, organ, or even 
entire organism. In its origins, proteomics was based on 2-D gel separation techniques and 
measured proteins with stains and antibodies.3 This allowed for only rudimentary 
characterization of proteomes. However, fueled primarily by innovations in instrumentation, 
proteomics has developed into a mature field using two-dimensional high performance liquid 
chromatography (LC) coupled to high-resolution tandem mass spectrometers (MS).4-7 In certain 
systems (like yeast), a nearly complete proteome coverage can be achieved with these methods.8 
Measuring relative levels of these proteins when comparing an experimental group to a control 
group can be very powerful in elucidating impacts of the treatment on the experimental group. 
This is commonly done to elucidate gene function (proteogenomics), probe for biomarkers, and 
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in pharmaceutical research.9-11 While this approach more closely probes molecular function, 
proteomics also has limitations.  
Despite the development of robust methodologies, there are still technical difficulties for 
proteomics. One such problem is that of quantification. Commonly, quantification is only 
performed in a relative manner, comparing two or more test conditions. Additionally, these 
values are based on peak areas of the MS1 data for peptides (in bottom-up, the most common 
proteomic technique). However, this can be misleading because of isobaric coeluting species that 
can greatly impact the accuracy of this quantification. Additionally, full-scans need to be 
balanced with fragmentations to both provide both deep peptide sequences and give accurate 
quantitative values.12 Additionally, there is no good way to go from peptide quantifications to 
protein quantification for large numbers of proteins due to differential ionizations, enzymatic 
cleavage efficiency, and protein/peptide losses across experimental steps. There are other 
challenges as well such as peptide identification, adequate sampling of membrane proteins, and 
accurately preserving post-translation modifications, but space does not permit a full description. 
Beyond the experimental and informatic challenges of proteomics, many proteins 
detected have unknown functions and kinetics. Additionally, it is difficult to predict how the 
thousands of proteins will interact to form the metabolic state of an organism. Experiments bear 
this out, where predicted states based on proteomics or transcriptomic data conflict with actual 
studies of the metabolites.13-14 This is hypothesized to be due to metabolic regulation being 
controlled through enzymatic efficiency, not capacity (pool-size).13 This is the gap metabolomics 
desires to fill—to discover gene functions, to characterize proteins, to elucidate signaling 
pathways, and determine the physiological impact of small molecules. Although there are 
different methods of attempting this analysis (nuclear magnetic resonance, Fourier transform 
infrared spectroscopy, etc…) we will be constraining our focus to liquid chromatography-mass 




Metabolomics in its fullest sense is the global analysis of all small molecules in a 
biological system (metabolites).15 This is an astoundingly ambitious goal. Thousands of 
metabolites are already known with the Human Metabolome Database listing 9037 metabolites 
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that have been detected in biological specimens (as of 1/9/2020).16 However, myriads more 
remain unknown and unverified with estimates of unique metabolites as high as 200,000.15 
Identifying and characterizing these compounds would open up worlds of biological knowledge; 
however, this presents several challenges. The first is that the possibilities are virtually endless. 
In the field of proteomics, peptide identification is greatly simplified by the presence of the 
genome. Proteins come directly from the genes (albeit some display modifications) and so by 
sequencing the genome, a reference guide of protein possibilities is generated. However, there is 
no such reference when it comes to metabolomics. Genetic or protein sequences do not provide a 
direct guide as to what reactions (and thereby what molecules) occur. Such determinations must 
be done through painstaking experimentation. Even if mass spectrometric measurements could 
be done to such a degree of accuracy that unique formulae were assigned to each spectral feature 
(which would require mass accuracies well below 0.1 ppm17—not possible outside of specialized 
ion cyclotron resonance instruments for the foreseeable future), the analyst is still far from a 
chemical structure, much less stereochemistry. Additionally, the lack of a “reference manual” 
means metabolite origin is difficult to determine. Metabolites analyzed from bovine serum for 
example, may be produced from bovine tissues or from the microbiota of its rumen. The same is 
true for plant-microbe interactions and other symbiotic organisms. Unclear origins such as these 
can be important depending on the biological question being asked.  
Not only are there vast numbers of compounds, with seemingly endless possibilities, but 
these span a broad range of polarity and other chemical properties. From glucose to cholesterol 
to odd compounds like cyanocobalamin (vitamin B12), metabolites are exceedingly diverse. 
Many of these metabolites are labile or volatile, which further complicates their capture and 
analysis. Beyond chemical variance, metabolites span a wide concentration range with estimates 
of at least twelve orders of magnitude (the best mass spectrometers can only touch six orders of 
magnitude).18  
The sheer number of metabolites also provides obstacles to analysis. Inevitably, 
metabolites coelute, which modern time of flight (TOF) and orbitrap instruments are able to 
resolve (except for compounds with the same mass), but if tandem MS data are desired, 
instrument duty cycles are not always fast enough to capture all coeluting compounds. Similarly, 
most instruments are not able to switch polarities mid-run effectively, which hampers broad 
metabolite coverage as some molecules feasibly ionize only in negative mode while others only 
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To summarize the current state of metabolomics, both the total number and identify of 
most metabolites is unclear; there is no single method capable of extracting all metabolites from 
a system, let alone analyze them; mass spectrometers cannot uniquely identify new metabolites 
or span the concentration ranges metabolites display and they lack the duty cycle to 
comprehensively annotate all metabolites in a mixture; finally, even with measured spectral 
features, we lack the ability to easily distinguish true signals from chemical and instrumental 
noise or to determine the biological significance of those signals. In short, a metabolomics 
experiment is doomed from the start. 
Although the ideal metabolomics experiment is far out of reach, we can divide this lofty 
goal into more manageable pieces. One customary division is the separation of lipids from polar 
metabolites. Although lipids are rightly considered a subsection of metabolites, they are 
convenient to separate from conventional water-soluble metabolites because of polarity 
differences. Lipid are relatively non-polar compounds (though there is no strict definition, they 
are generally agreed to be amphiphilic or hydrophobic hydrocarbon-based molecules). For this 
reason, aqueous-based extractions will miss much of the lipidome (an organism’s complete set of 
lipids), and it is typically better to dedicate a separate method for lipid analysis rather than 
hamstring the metabolomic analysis by trying to include lipids. Hydrophilic metabolites are often 
measured using various LC-MS based techniques (although capillary electrophoresis is 
sometimes used).19-21 LC is a technique that separates analytes based on differential affinities as 
they pass through a column. The eluent is then directed to a mass spectrometer (usually using 
electrospray ionization) that measures the compounds. The mass spectrometers measure mass to 
charge ratio (m/z) and assign intensities to each m/z. This is sometimes done in tandem where the 
molecule is fragmented, and the fragments measured. Metabolites are challenging to characterize 
for the reasons described above, including their chemical diversity, concentration ranges, and the 
lack of available information. Because of this, studies will often employ more than one analytical 
technique, combining different chromatography and mass spec polarities to increase metabolite 
coverage. 
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For lipid analyses, the lipidome is often further subdivided with amphiphilic, or charged, 
lipids (phospholipids for example) and hydrophobic, or neutral, lipids (steroids being a major 
class), again for practical reasons. Although often thought of as performing merely structural or 
energy roles in physiology, lipids are being found more and more to also play important 
signaling and regulatory roles. This is already well known in the case of steroid hormones, but 
others have been characterized including sphingolipids, eicosanoids, and inositol 
phospholipids.22-24 Amphiphilic lipids are generally analyzed by RPLC-MS, HILIC-MS, and 
direct infusion MS methods.25-28 Nonpolar lipids, on the other hand, have been analyzed by 
nonaqueous RPLC as well as normal phase methods.29-31 
Another practical subdivision of metabolomics is to dedicate specific methods to volatile 
metabolites. Many metabolomic extraction procedures involve a drying step in which volatiles 
are lost. These are best analyzed by gas chromatography (GC)-MS based methods. GC is a gas-
phase separation that is naturally suited to volatiles. However, due to the gas phase requirements 
and the high temperature, this is unsuited to non-volatile or thermally labile metabolites (such as 
sugars or nucleotides). It is worth noting, however, that non-volatile metabolites and lipids are 
sometimes analyzed by GC-MS using derivatization techniques, however, this introduction 
focuses on LC-MS methods. 
Beyond methods dedicated to certain classes of molecules, the analysis can be further 
focused by separating “targeted” and “non-targeted” analysis. In targeted lipid/metabolomics, the 
analysis is limited to a set of known compounds where absolute quantitative data are desired 
(where a value in molarity or g/L is generated). Non-targeted or discovery metabolomics instead 
tries to analyze an extensive array of metabolites, including unknown metabolites, while only 
employing relative quantification (relative quantification is fold change relative to a control). 
Generally, to get highly accurate reproducible quantitative data, the method must be set up to 
optimize (target) the instrument toward measuring the compounds of interest. If this is done, a 
global analysis is hampered by the method bias and cannot be as comprehensive. The method 
employed is dependent upon the question being asked. Often non-targeted metabolomics are 
used for “hypothesis generating” experiments. Targeted metabolomics, on the other hand, are 
often used to test hypotheses. Thus, it is not unusual for a targeted metabolomics experiment to 
be performed to explore and validate findings from a non-targeted experiment. 
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Important Developments 
There has been headway made in the pursuit of these sub-goals. Oliver Fiehn, along with 
Tobias Kind and others in his lab have established principals to guide unknown spectral feature 
formula assignment, facilitating untargeted analyses. They were the first to demonstrate that 
mass accuracy will never (in the foreseeable future) give the specificity required for unique 
formula assignment.17 Following up on that, in their “Seven Golden Rules for heuristic filtering 
of molecular formulas obtained by accurate mass spectrometry”32 paper, they describe seven 
rules which are helpful to reduce the number of possibilities generated from matching chemical 
formulae to experimental masses. The Fiehn lab has also established a popular metabolomics 
database containing chromatographic (GC) and tandem mass spec information for a wide variety 
of metabolites, the FiehnLib.33 
Regarding the separation half of the analysis, Joshua Rabinowitz and his lab made a 
significant contribution by their development and validation of chromatographic methods for 
metabolomics. In particular, he developed both HILIC-MS and RP-MS methods for non-targeted 
metabolomics.34-35 The RP method employs an ion-pairing reagent to improve retention of polar 
metabolites on the nonpolar column but keeping the robustness of a reversed phase packing.35 
This method has been utilized by others, demonstrating the versatility of the method.36-40  
One of the greatest achievements of the lipidomics field is the development of shotgun 
lipidomics. Unlike most methods utilizing separations, this involves the direct infusion of lipid-
rich extracts into the mass spectrometer. As such, this method is faster, easier, and much less 
expensive than those which employ chromatography (no solvent or apparatus costs). This was 
first developed by Han and Gross in 1994.27 They identified greater than 50 lipid species from 
human erythrocyte membranes with quantitative accuracies >95%. This approach is still used 
today for rapid profiling of phospholipid species. 
Overall, there have been strong developments made in metabolomics as a field, although 
there is still much to be done. We will now consider these advances and the current state of the 










To begin any metabolomics analysis, the first step must be extraction. To analyze 
metabolites, they must first be freed from the protective shell of the cell wall/membrane. As 
discussed, this looks different depending on the type of analysis being performed. Polar 
metabolites represent the most diverse and problematic of the metabolomic subsets. Several 
challenges immediately present themselves. First, in order to accurately represent the 
intracellular components of the sample (be it a culture, tissue, or other biomass) in the extract, 
the procedure must quench metabolism (stop enzymatic activity). To quench metabolism, 
temperature shocks are often employed, using liquid nitrogen or chilled solvent, but flash 
freezing is required if there is a delay between sample harvesting and extraction.41-43 
Additionally, the extraction method must be careful not to restore enzymatic activity later in the 
method. This is particularly an issue when the polar metabolites are concerned because aqueous-
based solvents do not halt enzymatic activity and the metabolic state will be perturbed. 
Therefore, most extraction solvents employ a polar organic component in the solvent to denature 
and precipitate proteins. Sometimes high or low pH is used to accomplish the same effect. 
However, the use of pH extremes for protein precipitation has been reported to result in lower 
reproducibly measured features, possibly due to degradation, co-precipitation, or ionization 
suppression of metabolites, or a combination thereof.44-47 
The extraction method and solvents also need to lyse cells and limit abiotic degradation. 
Solvents used for decades include perchloric acid,48 hot water,49 and boiling ethanol50 which 
were originally used to measure intracellular amino acid content. These are relatively harsh 
methods and since 1990 softer extractions method have been developed to prohibit metabolite 
degradation.51 Many studies employ some kind of chloroform/methanol extraction (CME). This 
is a biphasic extraction that can be utilized for collection of either metabolites or lipids. Cold 
methanol, chloroform, and water are sequentially added to the sample and mixed for several 
minutes to permeabilize and extract the contents of the cell.42 This methanol/chloroform mixture 
has the added benefit of precipitating proteins to stop potential enzymatic activity. After phase 
separation and centrifugation, the aqueous layer is collected for metabolite analysis. 
Perhaps due to the inconvenience of this lengthy extraction, or to avoid the use of 
chloroform, a probable human carcinogen, a cold methanol/water extraction protocol was 
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developed.52 This uses a simple 50/50 methanol/water solvent and freeze-thaw cycles to lyse 
cells and became commonly used.53 However, there have been some concerning reports 
questioning the efficacy of this extraction method. Rabinowitz and Kimball found that the cold 
methanol procedure “resulted in marked decomposition of nucleotide triphosphates.”53 Canelas 
et al. also found that cold methanol with freeze-thaw cycles did not stop enzymatic activity.51 
This is perhaps unsurprising since enzymatic activity has been assayed down to −100 °C in 
methanol solutions and may explain the observed loss of nucleotide triphosphates.51, 54 
Rabinowitz and Kimball developed an alternate extraction method to preserve unstable 
compounds like the triphosphates.53 This employed an acidic (0.1 M formic acid) acetonitrile-
based extraction (AAE) with either water or methanol and water as additional components in the 
solvent. They found that AAE performed better than cold methanol by limiting degradation and 
provided better yields for almost all metabolites than did CME.53 However, Canelas et al. tested 
AAE against CME and found opposite results.51 They attribute this discrepancy to the lack of 
mixing when Rabinowitz and Kimball tested CME as well as differences between model 
organisms (Rabinowitz used E. coli and Canelas used S. cerevisiae). In CME, the chloroform, 
methanol, and water will phase-separate into two layers requiring a period of mixing to achieve 
equilibrium partitioning of analytes. Without this mixing, it is conceivable that the extraction 
efficiency would decrease. 
CME preparations were first used for lipid analyses. Made popular by Folch’s papers in 
1951 and 1956, CME variants are still very common for lipid extractions.55-56 Folch’s method 
took advantage of the insolubility of chloroform in water to develop a two-phasic extraction 
similar to those already discussed that washes out impurities and leaves lipids in the chloroform 
layer. It used relatively large solvent amounts in an 8:4:3 ratio of chloroform, methanol and 
water. Bligh and Dyer developed a variant of the Folch method which is rapid and uses less 
solvent than Folch’s method.57 The general method is similar and uses a final mixture of 2:1:1 
chloroform, methanol, and water to extract lipids and wash contaminates. This seems to be very 
similar to the Folch method and may work better when the sample has a low mass fraction of 
lipids. At high mass fractions, however, Bligh and Dyer’s method does not give as high yields as 
Folch’s which makes sense since the smaller volume solutions may be saturating.58 
The diversity of extraction methods used complicates the comparison of different 
metabolomic studies. Are different findings the result of actual differences in the systems being 
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studied or are they artifacts of differences in the procedures used? Tentatively, CME seems to be 
the most reliable extraction method for metabolites when done correctly, although other methods 
may be better if a faster analysis is desired. Whereas for lipids, the Folch or Bligh and Dyer 
methods both work, depending on the sample. More work still needs to be done to validate and 
standardize extraction methods. In the meantime, however, data can be reasonably compared to 
each other for results generated in the same experiment. Although the absolute levels may be 
skewed from the original biological state (ATP/ADP ratio, for example), differences between 
samples ought to be reflective of real differences in the organism. However, particularly for 
metabolites known to be unstable, observed differences may be secondary, and so one must be 
careful when inferring biological conclusions. 
Recently, there has been increasing interest in developing extraction methods to 
simultaneously collect multiple classes of biological molecules. This is applicable to “muli-
omic” analyses where multiple omics experiments are performed in the same study. For 
example, a recent study employed metabolomics, lipidomics, and proteomics to elucidate the 
functions of mitochondrial genes/proteins.59 The benefit of doing a concerted extraction is that 
each molecular biome derives from the same biological state. Otherwise, it is hard to ensure 
different extractions are harvested at identical physiological conditions. Performing one 
extraction to collect three (or more) molecular classes also greatly reduces sample consumption 
and speeds sample collection. This is particularly advantageous when sample volumes are at a 
premium (as is often the case with clinical samples). The disadvantage is that the procedure 
cannot be optimized to focus on any particular set of compounds. This may reduce extraction 
efficiencies when compared to focused extraction procedures. Two such tandem extraction 
protocols were published in 2016, the so-called SIMPLEX (Simultaneous Metabolite Protein 
Lipid Extraction) and MPLEx (Metabolite, Protein, and Lipid Extraction) methods.60-61 These are 
both modifications of previously existing extraction methods, with SIMPLEX based on the 
Matyash lipid extraction (a biphasic MTBE/methanol/water extraction) and MPLEx based on the 
CME.56, 62 With SIMPLEX, the resulting extraction has lipids in the organic top layer, 
metabolites in the aqueous lower layer, and proteins pelleted at the bottom of the vial. When 
MPLEx is used, due to chloroform’s extreme density, the organic layer sits at the bottom of the 
vial and aqueous layer is at the top with proteins sandwiched between them. SIMPLEX expedites 
the process slightly by making fraction collection easier by pelleting out the proteins. However, 
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there has been no direct comparison of these two methods, and it is unclear what the different 
efficacies might be. 
 
Fractionation 
Extraction yields a very complex mixture of thousands of chemicals. For this to be 
analyzed precisely, the sample must be fractionated. A fractionation step helps to reduce ion 
suppression (an effect where certain molecules preferentially ionize over others, drowning their 
signal) and wash out other interfering species like salts, which may be present in the extract. If 
tandem MS data is desired, fractionation also allows time for analytes to be sequentially selected 
for MS2 analysis. There are drawbacks to a pre-MS fractionation, such as sample dilution and 
increased analysis time. However, the majority of the time, the benefits outweigh the negatives. 
In early metabolomics work (called metabolic fingerprinting), gas chromatographs were often 
employed.63-66 GC continues to be employed for metabolomic studies today, although LC-based 
methods are now more common.47, 67-69 Much could be said regarding GC metabolomics, but 
here we will be constraining our focus to LC-MS metabolomics. It is worth noting that GC 
metabolomics requires derivatization (for broad metabolite coverage) and still cannot be used for 
large or labile compounds.15 LC has also been used for metabolomic analysis. LC-MS started to 
be applied to metabolite analyses in earnest at the turn of the millennia (early 2000s or just 
before). These were focused studies, but such work laid the foundation for further expansion.70-73 
Reversed phase (RP) separations were commonly used due to their ease-of-use and column 
robustness. Retention presents a problem, however. RP separates based on analyte adsorption to 
a hydrophobic stationary phase, which can work for lipids (being relatively non-polar), but 
metabolite methods often suffer from poor retention. This leads to coelution of metabolites and 
elution in the dead-volume. Having several coeluting compounds increases the instrumental 
burden as separation does not resolve compounds with similar or identical masses. Second, salts 
and other contaminates often elute in the dead-volume, which causes ion suppression for early 
eluting analytes. Lu et al. report a method to quantify 90 metabolites using a Fusion-RP column 
(Phenomenex) with polar elements incorporated into the C18 stationary phase.74 The embedded 
polar elements provide some selectivity to polar metabolites allowing separation; however, even 
this is still hampered by retention issues and poor peak shape.75 Further improvements, were 
needed and there are two main substitutes to achieve superior separations for polar metabolites. 
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The first is Hydrophilic-Interaction Liquid Chromatography (HILIC). This uses a polar 
stationary phase (often silica), which builds up a water rich solvent layer.76 The dominant 
separation mechanism was thought to be through differential partitioning between the water layer 
(mostly static) and the organic rich mobile phase.77 However, other mechanisms are at play as 
well, including adsorption and ion exchange.77 HILIC gives superior retention for metabolites 
compared to RP, but chromatographic peak profiles for HILIC separations can often be poor. 
Bajad et al. in 2006 found good separation and peak shapes with an amino HILIC column.34 The 
amino functional groups on the stationary phase used are reactive, however, and the column 
lifetime is short. The second substitute takes the concept of adapting RP chromatography to polar 
analytes further. Lou et al. (later adapted by Lu et al.) added an ion-pairing reagent to the 
chromatography solvents (tributylamine, in this case).35, 78 This increases retention by forming a 
complex with charged analytes and the nonpolar functionality (butyl groups) serve to increase 
affinity to the stationary phase. By changing the selectivity this way, most metabolites elute past 
the dead volume and are more dispersed across the gradient. However, ion pairing reagents are 
not ideal for MS use. This is because they are permanently charged species that will cause severe 
ion suppression in their incompatible instrument polarity (positive mode for tributylamine). 
Additionally, ion pairing reagents tend to be extremely recalcitrant and stick to LC fittings, 
columns and MS components. The means that the ion suppression will persist even when using 
separate solvents. Despite these handicaps, some labs feel the benefits outweigh the 
complications and Lu’s ion pairing method has been used for wide metabolome coverage by the 
Campagna lab and others.38, 79-80 
For lipid fractionation, the methods used will vary based on the specific analytes of 
interest. For phospholipids (the most common amphiphilic lipids), fractionation is not always 
used as discussed in shotgun lipidomics. However, to improve coverage of amphiphilic lipids or 
simplify analysis chromatography is employed. RP methods have been developed for 
phospholipids. These roughly separate lipids based on tail chain length. However, based on the 
hydrophobic interactions between the fatty tails and aliphatic stationary phase, it can be difficult 
to elute lipids as they bind strongly to RP stationary phases. HILIC is also employed, which 
roughly separates lipids based on headgroup polarity. These interactions are less strong than with 
RP, allowing lipids to be more easily eluted from the column. This selectivity allows sequential 
analysis of lipid classes, simplifying analysis, especially when fragmentation is not employed. 
 
- 13 - 
 
The hydrophobic lipids are more challenging. RP methods have been attempted; 
however, many adaptations are required to avoid irreversible binding. Cai et al. developed a non-
aqueous RP technique, which uses APPI (atmospheric pressure photo ionization—one of the 
better methods of ionizing hydrocarbons) for MS analysis.29 They were working with 
triacylglycerols (one type of neutral, or nonpolar, lipids) and found that many nonaqueous 
solvent systems worked well but recommended acetonitrile/isopropyl alcohol for practical 
reasons. APPI with solvent additives (acetone) was demonstrated to give good signal with 
estimated LODs below 200pg. Normal phase chromatography-based methods have also been 
employed with good results. Hutchins et al. report a method for separation and analysis of 
cholesteryl esters, triacylglycerol, diacylglycerols, and monoalkyl-ether diacylglycerols using an 
MTBE/hexane gradient with a silica column.31 This was coupled to a MS by use of a splitting T 
and addition of an electrospray modifier solution. This was necessary because aprotic-nonpolar 
solvents such as hexane and MTBE do not spray in ESI. 
 
Mass Spectrometry 
Just as genomics was driven by technological and methodological innovations, so too 
metabolomics depends on development of analytical platforms sophisticated enough to handle 
the complex samples. Early metabolomics was done with triple quadrupole (QQQ) mass 
spectrometers. A quadrupole is a mass analyzer that filters out ions except for a particular m/z. If 
the ion flux is detected, an intensity can be assigned to the selected m/z. In a QQQ, the first 
quadrupole is used to select an ion (precursor or parent ion), which is fragmented in a second 
quadrupole, or higher order multipole, (which does not filter ions) and a product (or daughter) 
ion is selected in the third quadrupole. Depending on how the quadrupoles are operated, various 
different MS data can be generated with common modes including selected reaction monitoring 
(where specific parent and product ions are preset), product ion scan (where all possible product 
ions are scanned for particular parent ions), and neutral loss scans (where parent and product ions 
are scanned with a set m/z offset to see what ions lose a particular group). Due to the 
quadrupole’s low resolving power and cumbersome operation with large numbers of analytes, 
non-targeted profiling is functionally impossible and QQQ metabolomics are often operated with 
selected reaction monitoring of a few dozen targeted metabolites. Technological innovations 
have exploded analytical capabilities with the introduction of high resolution TOF and orbitrap 
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instruments. TOF instruments analyze ions by pushing them down a flight tube and measuring 
how long it takes to reach the detector. The signal intensity of the detector relates to the number 
of ions and the time relates to the m/z. When optimized, TOFs can have high resolution 
capabilities. An orbitrap injects packets of ions into a small cell with an electrode in the center. 
Ions orbit the electrode and oscillate along the length of the cell due to the shape of the cell. This 
oscillation is m/z dependent and analysis can be performed by measuring the induced current 
(image current) as ions oscillate across the football-shaped ion cell. This signal can be 
deconvoluted by a Fourier transform to generate ultra-high resolution data. These also have full 
scan capabilities, where the full mass spectrum (within the operating parameters of the 
instrument) is measured every scan. The resolving power improvements combined with full 
scans gives incredibly richer data sets than with quadrupoles. This allows for analyses of 
hundreds and potentially even thousands of compounds in the same experiment, even detecting 
unknown compounds, thereby unlocking the possibility of truly non-targeted experiments. 
Hybrid variants such as the Q-TOF and Q-orbitrap (the QE, or Quadrupole-Exactive, instrument) 
further improve analyses and are used more often for metabolomics than their single stage 
versions. These also allow for tandem MS to be performed except that the MS2 are performed in 
multiple reaction monitoring (MRM—where all possible daughter ions are detected) due to the 
full-scan capabilities of these instruments. For non-targeted experiments, these will often be 
operated in a data-dependent acquisition (DDA) mode. With DDA, the n-most intense ions of a 
full scan are sequentially selected for fragmentation (MRM in this case). This allows for 
profiling of unknowns as features can be selected for fragmentation without being known a 
priori. To efficiently perform DDA, a fast duty cycle is required such that a large number of ions 
can be selected for fragmentation in a short amount of time. Otherwise, rapidly eluting molecules 
might be missed by the MS2 scans. Or, even if they are measured, a chromatogram may not be 
able to be assembled from the full scans, as there are fewer datapoints. These principals apply to 
both metabolomics analyses as well as lipidomics. For metabolomics, ionization is almost 
exclusively done with electrospray ionization, whereas lipidomics sometimes employs 
atmospheric pressure chemical ionization or APPI that accommodate the greater hydrophobicity 
of lipids.29, 81-82 APPI and APCI both pneumatically aerosolize the LC effluent inside the 
ionization source. APPI ionizes the analytes by using an UV source which has a strong ionization 
efficiency for hydrocarbons, and APCI uses a corona discharge to ionize analytes which 
 
- 15 - 
 
generally form similar ions to ESI, while having a greater chance of adducts and in-source 
fragmentation. 
 
Shotgun Lipidomics Details 
In lipidomics, mass spectral analysis can be performed without being coupled to 
chromatographic separation. This “Shotgun Lipidomics” was developed primarily through the 
work of Han and Gross.27-28, 83 In shotgun lipidomics, lipid extracts are analyzed with mass 
spectrometry by direct infusion without fractionation. The use of collisional induced dissociation 
(CID) with a triple quadrupole instrument enabled Han and Gross to identify both the lipid 
headgroup and corresponding tails with greater than 95% accuracy and quantify with r-squared 
values of at least 0.99.27 
Perhaps surprisingly, shotgun lipidomics can also be used non-polar/neutral lipids. Han 
and Gross have also pioneered methods for the direct infusion ESI-MS/MS analysis of 
triacylglycerols (TAGs). This may be surprising because nonpolar lipids often have low 
ionization efficiencies, and solvents often used for neutral lipids are aprotic and do not spray 
well. To account for this, Han and Gross used a 50/50 chloroform:methanol solution that fully 
solubilizes the TAGs while still spraying in ESI.83 To facilitate ionization, lithium hydroxide was 
added forming lithiated TAG that ionizes in positive mode.83-84 This process allows not only for 
qualitative fingerprinting of TAG species but also quantitative analysis.83  
Tandem mass spectrometry with full-scan high resolution instruments such as Q-TOF 
and QE allow for head and tail profiling as well, but faster and with more information (each MS2 
scan captures all product ions).85-86 The improved power has been demonstrated with a shotgun 
lipidomics method employing both a tandem orbitrap and a Q-TOF that has been used to 
quantify 250 different lipids of 21 classes in yeast.87 This method developed by Ejsing et al. 
utilizes a two-step biphasic extraction to capture polar and nonpolar lipids. They analyze this 
extract via nano-ESI direct infusion and quantify lipids from the classes PC, LPC, PE, PG, PA, 
PS, LPS, PI, LPI, CL, LCBP, IPC, MIPC, M(IP)2C, DAG, TAG, LPC, and LCB. They estimate a 
95% lipidome coverage of their test species (S. cerevisiae). These are impressive results and 
display a robust methodology. However, the method uses multiple analysis methods which 
throttles throughput and low abundance lipids (which may be involved in signaling and the most 
biologically relevant) will be missed. 
 




All these different methods only process and measure samples. Once the measurements 
have been made, the instrument will output a matrix of retention time (when chromatography is 
employed), m/z, and intensity. This gives no biological information. How does one link the MS 
results to metabolites and explain biological relevance? Informatics. Many different informatic 
and statistical approaches are needed to interpret the vast amounts of data generated by typical 
metabolomics experiments. The approaches used vary depending on the experiment type. 
Targeted metabolomics experiments can often be interpreted by traditional analytical chemistry 
approaches. These include calibration curves, standard deviations, and the like. As for non-
targeted metabolomics, the task becomes much more difficult. Modern orbitrap and TOF 
instruments generate high-resolution full spectrum measurements multiple times a second. If the 
entirety of these scans taken across a thirty minute (or longer) chromatographic run are to be 
considered, there is far too much data to be annotated by hand. To begin the analysis, peak 
picking algorithms such as XCMS are often employed. XCMS (standing for any type of 
chromatography-mass spectrometry) was developed by the Suizdak lab for automated peak 
picking and non-linear retention time correction of metabolomic and lipidomic data sets.88 The 
benefits of peak picking are straight forward, allowing for the selection of thousands of features 
in a short period of time, but the benefits of non-linear retention time correction may not be 
intuitive. Across a sample set, retention times vary and drift differently for each analyte. One 
compound may have a longer retention time while a second has a shorter retention. This is 
especially true when the samples vary in composition, which can often be the case with extracted 
samples. Regardless of the cause, XCMS is able to correct for these unpredictable shifts and 
output high-quality lists of spectral features with minimal effort. XCMS is now available as an 
online open access program that allows for rapid annotation of chromatography-mass spectral 
data. 
After generating a list of possible metabolites, the task of parsing through and 
distinguishing information from noise can begin. The first steps usually taken are to try to 
identify adducts or isotopes and remove or consolidate them to ensure one peak per compound. 
This is usually done by a taking a peak and looking for features that are aligned in the time 
domain but shifted in the mass domain by a known amount (the mass of an adduct or isotope). 
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There are different scripts that can perform this task including CAMERA,89, MetAssign,90 or 
AStream.91 This consolidation helps reduce the amount of data to be analyzed and greatly 
reduces redundancy, which can skew interpretation, particularly for multivariate analyses like 
principal component analysis (PCA) or partial least squares-discriminant analysis (PLS-DA). 
These statistical methods are helpful in describing relationships between sample sets. These 
attempt to discern relationships between groups by reducing the data to eigenvectors, which 
describe the variance between samples. This is a good way to visualize the differences between 
several samples over many data points. Without reduction of dimensionality in this way, such 
differences would be obscure to incomprehensible. Although similar, PCA and PLS-DA differ in 
significant ways. Primarily, PCA is an unsupervised analysis, whereas PLS-DA is an 
unsupervised analysis. This means that PCA attempts to plot whatever major differences exist 
between input samples, whereas PLS-DA plots the differences between samples so as to 
maximize the covariance between assigned groups. Practically, this means that PCA is not as 
sensitive as PLS-DA is to subtle differences between groups. PLS-DA, on the other hand, can be 
prone to overfitting. Overfitting is when the model finds and overemphasizes small differences 
between groups that may just be due to chance. So, PLS-DAs must be used carefully to avoid 
this issue. Beyond qualitatively distinguishing between sample groups, these are useful in 
hypothesis generation as well. The eigenvectors, which show separation between groups, can be 
deconstructed and “loadings” (weighted contributions to the separation) can be generated for 
each variable (spectral feature or analyte). Analytes with large loadings show significant 
deviation between groups and may be important features associated with the test variable. These 
analytes might form the basis of a future targeted analysis to validate and elaborate what the 
meaningful differences might be. Heatmaps are also helpful in this regard. These graphically 
display the foldchange associated with different features and will sometimes also display 
statistical significance in the form of a T-test p-value. This has the advantage over PCA and 
PLS-DA of displaying magnitude as well as statistical significance in feature variation. 
MAVEN is an opensource software for metabolomics data processing that attempts to 
integrate the preprocessing with visualization, one of the first to do so.92 This can be operated in 
a fully automated process, useful for non-targeted metabolomics, or manually by imputation of 
masses or standards lists and either manual or automatic integration of extraction ion 
chromatogram (EIC) peaks. It utilizes a retention time alignment mechanism similar to XCMS. 
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Visualization is facilitated by the automatic generation of EICs for features. Additionally, isotope 
peaks can also by generated and included in the data output through a simple GUI.  
 
Unknown Identification 
It is rare for spectral features to be easily assignable to specific metabolites. Often 
features are ambiguous and even when they are annotated by software, these assignments are 
putative and not always reliable. De novo identification of these features is a very complicated 
task. The first step is generating possible formulae from the exact mass. There are various 
programs capable of doing this. Normally, some filtering occurs at this step. This is because 
some formulae that may mathematically match the observed mass are obviously false. For 
example, both [C6H12O9P]
− and [H23BrNO5SP]
− may fit an observed 259.0218 m/z (with less 
than 1 ppm mass accuracy); however, the latter can be rejected as highly improbable. Therefore, 
generators will commonly apply constraints based on unsaturation or limitations on the possible 
number of uncommon elements. However, a more rigorous filtering can be applied to narrow the 
options further. Such a process was first described by Kind and Fiehn in 2007.32 They employ six 
or seven (depending on the type of analysis) metrics to filter mathematically possible formulae, 
the so called “Seven Golden Rules.” Two of these seven rules have already been mentioned, 
restrictions on element numbers and ratios. A third rule employed attempts to determine the ion 
adduct detected (typically [M+H]+ in electrospray) and then determine if the neutral compound is 
stable. This would filter out species based on unbalanced valences (improbable radical species 
for instance). A fourth rule is an isotope pattern filter. This attempts to narrow the possibilities by 
eliminating formulae that do not correspond to the observed isotope pattern. This can be 
particularly determinative for elements with unique isotope distributions such as chlorine, 
bromine, and sulfur. Rule five applies a heteroatom to carbon ratio check as this will be a small 
number for most compounds. Rule number six is used as a follow-up to element ratio check 
where formulae with several high element ratios are filtered. The example given is formulae like 
C26H28N17O1P3S8, which “would pass all rules so far including the element ratio check; however, 
the combination of high element ratios would still be too improbable.”32 Finally, the seventh rule 
is a trimethylsilyl (TMS) group check. TMS is a derivatizing agent used to make polar 
compounds volatile. This is used often with GC-MS metabolomics, but this rule is not used 
outside of that niche. These rules eliminate 92% of the hypothetically possible formulae (with 
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only C, H, N, S, O, and P) below 2000 Da. Additionally, for high quality spectra, the compound 
can be correctly mapped to compounds existing in a database with 98% accuracy (larger 
databases like PubChem show lower accuracy but still >88%), see Figure 1 for a graphical 
representation. It is worth noting that the results in Figure 1 are based on cumulative FPR, and so 
the actual accuracy for high mass compound is less than displayed by the graph. Regardless, the 
seven golden rules paradigm is very useful and lays the groundwork for further improvements to 
shrink the possible formulae even more. Many current formula generators incorporate at least 
some of the rules described here. 
A more common method of metabolite identification is simply to compare m/z values 
(combined sometimes with isotope intensities, retention times, or MS2 spectra) to libraries. This 
is facilitated by high mass accuracy instruments as the better the accuracy the better the library 
matches. There are various databases, including the FiehnLib already mentioned, but also 
MetaCyc, Lipid Maps, MassBank, KEGG, Human Metabolome Database, and even PubChem 
can be searched.16, 33, 93-98 This is very powerful as a high-throughput method of metabolite 
identification; however, since most of these are not easily searched with MS2 data and retentions 
times are rarely meaningful unless the method is copied exactly, such searches are often 
restricted to a sheer exact mass matching. This performs better than merely calculating possible 
formulae, but it still is powerless to resolve isobaric metabolites which can be common. 
 
Biological Interpretation 
These processing steps of generating and validating an annotated list of features are really 
pre-steps to facilitate biological interpretation. Although this is the ultimate goal of the analysis, 
it can take different forms. Due to the rapidly shifting nature of metabolism, the most important 
factor is reproducibility/statistical significance. Vast metabolite pool size changes can occur as a 
result of factors as simple as different delays before quenching. Care must be taken to filter 
irreproducible features as these are likely artifacts of the labile nature of metabolism. When 
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Figure 1-1. Seven Golden Rules False Positive Rate. False positive rates for seven golden 
rules analysis of 2,400 DrugBank molecules with a simulated ±3 ppm accuracy 
and ±5% isotope ratio error based on compound mass. The red curve shows the 
cumulative FPR (when the correct assignment is not in the top 3 results) for 
formula assignment without database query. The blue and green curves show 
cumulative FPR (considering only the top result) for formula assignment with 
database query, PubChem and DrugBank, respectively. Reproduced from ref32 
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biomarker discovery is desired, the biological analysis can be as simple as generating a volcano 
plot or its equivalent. A volcano plot plots the fold-change and statistical significance (p-value) 
of each feature relating a test group to a control. Potential biomarkers are features with both high 
fold changes and significance and are easily identified by such a graph. 
For a more detailed biological analysis, there are different options such as 
MetaboAnalyst.99 MetaboAnalyst is a free program that can take metabolite inputs and describe 
the pathways involved in the observed changes. This can be illuminating depending on the 
experiment; for example, a pathway suppressed in a gene knockout could indicate that gene 
encodes an enzyme in the pathway or else is involved in its regulation. MetaboAnalyst allows for 
the integration of other data sets including genomics or multiple metabolomics experiments. This 
program is convenient and user-friendly interface and facilitates analysis. 
Unknown metabolites are more challenging. If the metabolites demonstrating the greatest 
changes from a treatment are unannotated, it is not possible to say what metabolomic networks 
they are affecting. The simplest way to treat these is to designate them as biomarkers and analyze 
them as discussed previously. Biomarkers are biological signals that correlate with a biological 
state and can be used as a diagnostic tool. This has been done in several metabol/lipidomic 
studies for diseases including traumatic brain injury, Alzheimer’s disease, and cancer.100-102 
However, outside of disease profiling experiments, biomarkers are not relevant and other 
techniques must be employed to extract meaningful biological conclusions. There has been some 
interest in using van Krevin diagrams to visualize non-targeted metabolomics data.103 Van 
Krevelen diagrams plot features with assigned formulae based on their carbon to hydrogen and 
carbon to oxygen ratios. This can be helpful because different classes of compounds tend to have 
certain ratios. This allows features to be sorted by their probable metabolite class, allowing some 
speculation into biological function. Figure 2 displays metabolomics data visualization using a 
van Krevelen diagram. 
 
Specific Contributions 
In this diverse and complicated field, my research has focused on two areas. The first, is 
the application of metabolomics in a multi-omics experiment to expand the scientific knowledge 
base of metabolism. Specifically, chapter two describes an integrated metabolomics and 
genomics experiment done in collaboration with Dr. Kania in the Department of Biomedical and 
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Van Kevelen visualization of Metabolomics Data 
 
Figure 1-2. Utility of van Krevelen Diagrams for Metabolomics Visualization. A 
visualization of metabolomics data using a van Krevelen diagram. This was 
generated using the program OpenVanKrevelen.103 Metabolites are plot based on 
their expected hydrogen to carbon and oxygen to carbon ratios. Blue dots also 
have nitrogen in the predicted formula, while red dots do not. The opaque dots 
have more features associated with them.  
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Diagnostic Sciences to characterize the metabolic pathways of clinically relevant Staphylococcus 
isolates. This is an example of a metabolomics experiment which helps to shrink the knowledge 
gap by applying established metabolomic tools to elucidate the metabolic web while guiding 
medical treatment of potentially lethal bacterial infections. 
The second area is in the advancement of metabolomic techniques for better multiomic 
analyses of bacteria. Chapter three describes work done to validate different multiomic 
extraction techniques and critically evaluate them based on their extraction efficiency. These 
were tested on their ability to collect metabolites, lipids, and proteins in a simultaneous 
extraction, and found to be viable for multi-omics applications. This was a collaborative work 
with Dr. Hettich in the Microbiology Department and is important to guide future multiomic 
experimentation by providing a strong extraction protocol that will conserve sample, save time, 
and give more accurate results. These both demonstrate metabolomics is a varied and 
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Chapter 2: Metabolomics Applied: A metabolomic and genomic investigation of 
Staphylococcus isoprenoid synthesis 
This chapter contains material that is in preparation to be included in a future publication 
titled: Whole Genome Sequence and Comparative Genomics and Metabolomics Analysis of 
Human and Canine Staphylococcus schleiferi isolates. The proposed authors are Mohamed A. 
Abouelkhair, Matthew J. Keller, Hector F. Castro, Shawn R. Campagna, and Stephen A. Kania. 
SAK, MAA, SRC, and HFC contributed to the conceptualization of the project and experiments. 
Experiments were conducted by MAA and MJK. Formal analysis was performed by MAA, 
MJK, and SAK. Writing of the original manuscript was done by MAA and MJK with edits by 
MAA, MJK, SRC, and HFC. This has been adapted more fully for this thesis. 
 
Introduction 
Bacterial species of Staphylococcus are one of the most common causes of disease. In 
2017 alone there were 119,000 bloodstream Staphylococcus infections (not including skin 
infections) which led to 20,000 deaths.104 Many of these infections are thought to be caused by 
Staphylococcus aureus. However, there is growing evidence that other species of Staphylococcus 
are often misidentified as S. aureus. Two species in particular, S. schleiferi and S. 
pseudintermedius, are more commonly associated with disease in canines but been shown to also 
cause disease in humans.105-114 Both S. schleiferi and S. pseudintermedius are easily (and 
potentially often) mistaken for S. aureus.114-115 Antibiotics are an important defense against 
Staphylococcus infections, however, antibiotic resistance presents problems with methicillin-
resistant strains of S. schleiferi and S. pseudintermedius as well as the more common methicillin-
resistant S. aureus.113, 116-117 These species, then, are a danger to public health and challenge 
health care as better diagnostic and treatment options are needed. 
Isoprenoid biosynthesis is one of the essential metabolic pathways and is very similar 
between bacteria, eukaryotes, and plants.118-119 Different species of the staphylococcus genus are 
known to use different pathways of isoprenoid biosynthesis. S. aureus has been shown to use the 
mevalonate pathway for isoprenoid synthesis while others such as S. schleiferi and S. 
pseudintermedius have been shown to use the non-mevalonate pathway.120-121 This metabolic 
difference was proposed to be related to the host species as a critical intermediate in the non-
mevalonate pathway triggers an immune response in human and primate hosts and the 
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mevalonate pathway could be a virulence factor in S. aureus.121 Additionally, fosmidomycin, a 
phosphonic acid derivative that has been used to target the non-mevalonate pathway via 
inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr) is identified as a 
promising antimicrobial to specifically treat staphylococcus species infecting animals.121 
This problem is one that is naturally suited for metabolomics investigation, the 
mevalonate and non-mevalonate pathways have several unshared intermediates which should 
give a relatively easy way to distinguish the metabolic pathway used. In this experiment a semi-
targeted metabolomic analysis is employed to characterize the pathway used and comparative 
genomics is used to go deeper into the differences between the bacterial species and confirm 
metabolomics findings. This demonstrates the synergistic effect of using multiple omics 
techniques for biochemical investigations. 
 
Materials and Methods 
Bacterial Strains, Media and Growth Conditions  
Bacteria propagated in this study included five S. schleiferi isolated from human cases in 
the USA (191, 192, 196, CDC:132-96, CDC: 78-04) and the S. schleiferi subsp schleiferi type 
strain ATCC43808 isolated from a human patient in France. A single bacterial colony of each 
strain grown on blood agar plates was inoculated into 5 mL of sterile tryptic soy broth (TSB) 
(BD Biosciences, USA; Cat. no. RS1-011-21) and incubated overnight at 37 °C with shaking at 
225 rpm.  
 
DNA Extraction, Library Preparation and Whole Genome Sequencing 
DNA extraction was performed using the MasterPure DNA purification kit (Epicentre, 
USA; cat. no. MCD85201) according to the manufacturer's instructions. Libraries for sequencing 
were prepared using the Nextera DNA sample prep kit (Illumina, Inc., USA) according to the 
manufacturer's instructions. The genomes were sequenced using a MiSeq platform (Illumina, 
Inc.) with two runs (75 bps forward and reverse) at the University of Tennessee Genomics Core 
facility. Sequences were trimmed using BBDuk and de novo assembled using Geneious Prime® 
2019.0.4.122 A quality assessment tool for genome assemblies (QUAST) was used to assess the 
quality metrics of the assembled genomes 123. Annotation was performed by the NCBI 
Prokaryotic Genome Annotation Pipeline version 4.6 
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(https://www.ncbi.nlm.nih.gov/genome/annotation_prok) using the best-placed reference protein 
set with GenMarkS+. 
 
Comparative Genomics Analysis 
For comparative genome analyses, five canine S. schleiferi isolates (S. schleiferi 1360-13, 
S. schleiferi 2142-05, S. schleiferi 5909-02 and S. schleiferi 2317-03 with accession numbers 
of CP009470, CP009762, CP009676 and CP010309, respectively) were used in addition to S. 
pseudintermedius HKU10-03 (NC_014925.1), S. pseudintermedius ED99 (NC_017568), S. 
lugdunensis HKU09-01 (CP001837), S. lugdunensis N920143 (FR870271.1), S. 
epidermidis ATCC 12228 (NC_004461), S. epidermidis RP62A (NC_002976.3), S. 
aureus subspecies aureus ST398 (NC_017333), S. aureus subspecies aureus USA300_FPR3757 
(NC_007793), S. aureus subspecies aureus COL (NC_002951), and S. 
aureus subspecies aureus NCTC 8325 (NC_007795). A circular graphical display of the 
distribution of the annotations in each human S. schleiferi genome was performed using Circos 
124, then whole genomes were aligned using the Basic Local Alignment Search Tool (BLAST, v. 
2/2/22) .125 Pan/core-genome sizes were computed using the MicroScope gene families 
(MICFAM) based tool which uses an algorithm implemented in the SiLiX software 
(http://lbbe.univ-lyon1.fr/-SiLiX-.html): a single linkage clustering algorithm of homologous 
genes sharing an amino-acid alignment coverage and identity above 80%. Core-CoDing 
sequence (CDS), variable-CDS and strain specific sizes were determined.126 Phage prediction 
was performed using PHAST (PHAge Search Tool) (available at 
http://phast.wishartlab.com/).127 The presence of Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPRs) was evaluated as had been done previously.128 
Functional gene categories were determined with the Rapid Annotation using Subsystem 
Technology (RAST) v. 2.0.129 Metabolic pathway reconstructions of each strain were compared 
using the terpenoid backbone biosynthesis pathway from KEGG.  
The nucleic acid sequence of sodA from 20 staphylococcal species were aligned using the 
clustalW algorithm implemented in the software Geneious Prime® 2019.0.4 122 and the 
phylogenetic tree was constructed using the tree-building algorithm Neighbor-Joining with the 
Jukes-Cantor distance estimator implemented in Geneious Prime® 2019.0.4. The sodA gene 
sequence from Macrococcus caseolyticus was set as the outgroup. 
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Metabolic Pathway Analysis 
To elucidate the metabolic pathway used for isoprenoid synthesis in different strains of 
Staphylococcus, relevant metabolites were analyzed from cellular extracts to compare pool size. 
Two isolates of S. aureus were tested as well as five S. schleiferi isolates and one S. 
pseudintermedius. Isoprenoid metabolites were analyzed, including isopentylpyrophosphate 
(IPP), 2-C-methyl-D-erythritol-phosphate (MEP), mevalonate, phosphomevalonate, and 
geranyldiphosphate (GPP). These were examined using an established metabolomic method. 
This method was performed in a “semi-targeted” manner in that metabolites were annotated 
based on exact mass and retention time compared to a standard library. This was not a full non-
targeted method as features without standards were not investigated (excepting 
phosphomevalonate), but was not a true targeted experiment as the instrumental system was not 
biased toward detection of particular compounds, nor was analysis limited to a subset of 
metabolites with internal standards.  
Standards were purchased for three metabolites involved in isoprenoid biosynthesis. 
These were isopentylpyrophosphate (IPP), 2-C-methyl-D-erythritol-phosphate (MEP), and 
mevalonate. Mevalonate (pn: 42147) was purchased from Sigma as an analytical standard. MEP 
(pn: 52131) was purchased from Sigma but was reagent grade. IPP was purchased from Fisher 
(pn: I00501MG) also as reagent grade. Reagent grade was considered to be acceptable since the 
standards were used only to establish retention times and not for quantification. 
Geranyldiphosphate had been previously annotated using this method and no standard was used 
in this experiment.  
 
Extraction of Metabolites 
For the metabolomics experiment isolates S. schleiferi 192, S. schleiferi 196, S. schleiferi 
132-96, S. schleiferi 182159, S. schleiferi 182116, S. pseudintermidus 06-3228, S. aureus 
USA300, and S. aureus ST398 were used. Metabolites were extracted from bacterial cultures 
using a modified method based on a procedure by Rabinowitz and Kimball.53 5 mL of each 
culture were vacuum filtered through nucleopore polycarbonate filters to collect cells (Whatman, 
Little Chalfont, U.K.). The cultures were analyzed in biological triplicate. The filters were then 
placed cell side down into petri dishes containing 1.3 mL of extraction solvent (40:40:20 HPLC 
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grade methanol, acetonitrile, water with 0.1% formic acid). The solvent and dishes had been pre-
chilled in a –20 oC freezer while the filtration was set up. The filters in the solvent were placed at 
–20 oC, to facilitate extraction of metabolites, for 20 min. The following steps were completed in 
a 2 oC cold room. Filters were rinsed with the extraction solvent, and the suspension was 
transferred into a 2 mL centrifuge tube. An additional aliquot of extraction solvent (400 µL) was 
used to wash the filters, and this was added to the other 1.3 mL aliquot in the centrifuge tubes. 
The tubes were centrifuged at 13,000 xg for 5 min, and the supernatant was transferred to a 
second tube. A further aliquot of extraction solvent (200 µL) was used to resuspend the 
remaining cell pellet, and this suspension was allowed to extract at –20 oC for 20 min. The 
resulting supernatant was collected via centrifugation as explained above, and this second 
extraction was added to the first. All samples were then dried under a stream of nitrogen (there 
was some sample loss at this step due to the nitrogen spray splashing samples). The dried 
material was stored at –80 oC before thawing and resuspension in HPLC grade water (300 µL) 




Samples were analyzed with an established metabolomics method35, 130 using an Ultimate 
3000 UPLC (Dionex, Sunnyvale, CA) coupled to an Exactive Plus Orbitrap (Thermo Scientific, 
Waltham, MA). Briefly, 10 μL of each sample were injected onto the UPLC and separated with a 
Synergi Hydro-RP column (Phenomenex, Torrance, CA) using a gradient of 97:3 
water/methanol containing 15 mM acetic acid and 11 mM tributylamine as an ion pairing reagent 
(solvent A) with pure methanol (solvent B). The gradient was as follows: from 0 to 5 min solvent 
B increased from 0% to 20%, from 5 to 13 min B increased from 20% to 55%, from 13 to 15.5 
min B increased from 55% to 95% and was held constant. B then decreased to 0% at 19 min and 
was held until 25 min. The MS was operated using electrospray ionization in negative ion mode 
(3 kV spray voltage) with a resolution of 140,000. The automatic gain control was set at 3 x 106 
with a maximum injection time of 100 ms and the s-lens RF level was set to 50. The sheath gas 
flow was 25, auxiliary gas 8, and sweep gas 3 (all arbitrary units). The scan range was 72 to 800 
m/z for the first 9 minutes and then 110 to 1000 for the remaining 16 min. 
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Data Analysis 
MS convert131 was used to convert data from RAW to mzML file types132. Spectral 
features were evaluated using the open source software MAVEN92 and were assigned to 
metabolites based on retention time and exact mass. Metabolites where none of the sample 
intensities were 3x greater than the media blank were eliminated from further analysis. 
Metabolite intensities were then normalized using the optical density at 600 nm for each culture. 




When the standard of isopentylpyrophosphate (IPP) was analyzed using the UPLC-
HRMS method, only the monophosphate form was detected on the mass spectrometer, not the 
pyrophosphate. Given the instability of pyrophosphates, is not surprising that IPP would 
hydrolyze on column (or in stock solution) into isopentylmonophosphate (IMP). This IMP peak 
was assigned to IPP and analyzed as such.  
GPP was below the detection limit and was not measured. IPP was detected (as the IMP 
ion) with low intensities in the samples near or at background and so was dropped from further 
analysis. MEP was measured, but had noisy, low intensity peaks which limit the conclusions that 
can be drawn. Mevalonate had intense peaks matching the standard’s retention time. 
Phosphomevalonate was putatively identified without a standard. A distinct peak at m/z 227.0327 
was observed in the samples (corresponding to the phosphomevalonate [M–H]– exact mass with 
a 2.8 ppm accuracy). The C13 isotope peak of the feature was about 6.7% of the parent peak. 
This is consistent with phosphomevalonate having six carbons in its formula. Searching 
phosphomevalonate’s neutral mass on the Human Metabolome Database (HMDB) with a 20 
ppm window gives only 5-phosphomevalonate as a possible metabolite.97 The mass spectral data, 
then, is consistent with the 227.0327 m/z peak assignment as phosphomevalonate and there seem 
to be few other biotic options that fit the mass. 
 
Metabolomic Results 
The metabolomics run generated data for 91 metabolites that correspond to a previously 
run standard’s exact mass and retention time. The full list can be seen in Table A-1, A-2, and A-
 
- 30 - 
 
3 (see appendix). For the isoprenoid pathway metabolites, the results can be seen in Figure 2-1. 
There were no large differences between the different strains in the 2-C-methyl-D-erythritol-
phosphate (MEP) pool size observed, however strains 192 and 214 were somewhat lower than 
the other strains. The variations were not overly high (all relative standard deviations (RSDs)  
 below 30% except for USA 300 with 36%). 
Mevalonate and Phosphomevalonate were both orders of magnitude higher in the S. 
aureus isolates than in the S. schleiferi or S. pseudintermedius isolates. These differences 
between groups were statistically significant (p values <0.003 for mevalonate and p-mevalonate). 
Mevalonate also showed low variation between biological replicates (RSD ≤ 23%), except for 
strains 192 and 132-96 where the RSD was 55% and 57% respectively. RSDs of mevalonate and 
phosphomevalonate are especially low for both S. aurues strains. Given the high intensities, 
detector saturation could play a factor in this, however the C13 isotope peaks followed a very 
similar pattern as did the monoisotopic peaks, indicating that this pattern reflects the 
concentrations present in the isolates. 
 
Genomic Features of Human Staphylococcus schleiferi 
The genome size, GC content, predicted coding sequences and predicted RNAs of the 
five S. schleiferi isolated from human cases in USA (191, 192, 196, CDC:132-96, CDC: 78-04) 
and the S. schleiferi subsp schleiferi type strain ATCC 43808 isolated from a human patient in 
France are listed in Table 2-1. A circular graphical display of each genome of human S. 
schleiferi isolates was constructed to show the distributions of the contigs, CDS, RNA genes, 
CDS with homology to known antimicrobial resistance genes, CDS with homology to known 
virulence factors (Figure 2-2). A blast atlas where S. schleiferi subsp. schleiferi ATCC 43808 
was used as a reference against which the similarity of 10 other S. schleiferi genomes is shown 
(Figure 2-3). Regions are displayed where there is similarity between the reference genome and 
one of the related genomes. The plot shows the variation between human S. schleiferi (192, 
CDC: 132-96, CDC: 78-04, 191, 196 and S. schleiferi subsp. schleiferi ATCC 43808) and canine 
S. schleiferi isolates.  
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Figure 2-1. Isoprenoid Metabolite Bar Graph. The normalized intensity for each of the 
detected isoprenoid metabolites are shown for each strain. The biological 
replicates are averaged with error bars calculated using the standard deviation. 
The intensities have been set on a log scale to better display the differences. A is 
S. aureus USA300, B is S. aureus ST398, C is S. pseudintermidus 06-3228, D is 
S. schleiferi 182116, S. schleiferi 182150, S. schleriferi 192, S. schleiferi 196, S. 
schleiferi 132-96. Note that both S. arueus strains have high values of mevalonate 
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Table 2-1: Genomic Features of Human Staphylococcus schleiferi. The details of the genomic data for each sequenced S. 
schleiferi isolate is give. *WGS: whole genome sequence. 
Strain WGS accession No* No of contigs N50 (bp) Genome length (bp) G+C content (%) Predicted coding sequences Predicted RNAs 
191 PNRJ00000000 51 138,893 2,508,133 35.73 2,294 72 
192 POVG00000000 102 59,786 2,452,487 35.87 2,203 74 
196 POVH00000000 56 110,279 2,508,604 35.74 2,299 74 
CDC: 132-96 POVI00000000 92 56,958 2,468,342 35.92 2,218 76 
CDC:78-04 POVJ00000000 94 57,247 2,469,699 35.92 2,216 76 
ATCC 43808T POVK00000000 88 56,938 2,469,638 35.92 2,218 73 
 
 





Figure 2-2. A Circular Graphical Display of Human S. scheiferi Isolates. This includes, 
from outer to inner rings, the contigs, CDS on the forward strand, CDS on the 
reverse strand, RNA genes, CDS with homology to known antimicrobial 
resistance genes, CDS with homology to know virulence factors, GC content and 
GC skew. The colors of the CDS on the forward and reverse strand indicate the 
subsystem to which that these genes belong. 
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Figure 2-3. S. schleiferi Blast Atlas of Human and Canine S. schleiferi. The blue triangle and arrows show the variation 
between human S. schleiferi (192, CDC: 132-96, CDC: 78-04, 191, 196 and S. schleiferi subsp. Schleiferi ATCC 
43808) and canine S. schleiferi isolates. 
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Pan/Core Genome of Human S. schleiferi 
To establish an accurate genomic comparison at the whole genome scale, the pan-genome 
of the six human S. schleiferi isolates was defined using MICFAM with 80% amino- acid (A.A) 
identity and 80% A.A alignment coverage. The pan-genome includes two distinct constituents, 
the core and variable genomes. The core genome contains gene families common to all strains 
while the variable genome is composed of gene families present in at least two strains and absent 
in at least in one strain. The pan-genome of human S. schleiferi isolates consists of 3011 families 
and 12,268 genes and a core-genome consisting of 2004 families and 10,073 genes whereas the 
variable-genome consists of 1007 families and 2195 genes (Figure 2-4). The human S. schleiferi 
pan genome was classified into four categories and calculated the number of genes for each 
genome (Table 2-2) (Pan CDS, core CDS, variable CDS and strain specific CDS). 
 
Further Genomics Data 
Phage prediction was performed using PHAST (PHAge Search Tool). A complete 
(intact) prophage (PHAGE_Staphy_EW_NC_007056) was found in S. schleiferi CDC: 78-04, S. 
schleiferi 191, S. schleiferi subsp. schleiferi ATCC 43808 and S. schleiferi CDC: 132-96 (Figure 
2-5) with sizes of 41.2 Kb, 43.2 Kb, 42.2 Kb and 42.2 Kb, respectively. This prophage contained 
a minimum of seven hypothetical proteins in all three human S. schleiferi isolates. In addition, S. 
schleiferi 191 has an intact 9.4 Kb prophage (PHAGE_Staphy_phiPV83_NC_002486) whereas 
S. schleiferi 196 has incomplete prophages with different sizes.  
Presence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) was 
evaluated for the six human S. schleiferi isolates. One CRISPR array with five repeats (average 
repeat length was 36 nt and average spacer length was 30 nt) was found in S. schleiferi subsp. 
schleiferi ATCC 43808, S. schleiferi CDC: 132-96 and S. schleiferi CDC: 78-04. There are two 
CRISPR arrays in S. schleiferi 191 and S. schleiferi 196, the first array consists of seven repeats 
(average repeat length is 36 nt and average spacer length is 29 nt) and the second array consist of 
only four repeats (average repeat length is 36 nt and average spacer length is 36 nt). No CRISPR 
array was identified in S. schleiferi 192. 
Metabolic pathway reconstructions of each strain were compared using the terpenoid 
backbone biosynthesis pathway from KEGG and verified in the MicroCyc metabolic database. A 
hierarchical clustering created 9 clusters based on similar subsystems profiles (a, b, c, d, e, f, g, 
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Figure 2-4. Comparison of Shared Genes in S. schleiferi Isolates. Venn diagram showing 
shared and unique genes in human S. schleiferi isolates. Numbers inside the 
circles indicate the genes shared among genomes. 
 
Table 2-2. Pan Genomics CDS Breakdown. List of Pan CDS, core CDS, variable CDS 
and strain specific CDS count and percent for each human S. schleiferi genome.  














S.schleiferi 192 2383 2382 2014 368 84 84.551 15.449 3.526 
S.schleiferi CDC: 78-
04 
2414 2411 2017 394 36 83.658 16.342 1.493 
S.schleiferi CDC: 
132-96 
2424 2422 2018 404 31 83.32 16.68 1.28 
S.schleiferi 191 2517 2516 2013 503 36 80.008 19.992 1.431 




2421 2419 2014 405 44 83.258 16.742 1.819 
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h, j), each cluster showing the subsystems variation that were absent from the group of 
staphylococcus isolates but present across all other species examined (Figure 2-6).  
The Neighbor-Joining phylogenetic tree constructed from the Staphylococcus superoxide 
dismutase gene (sodA) is shown in Figure 2-7. The sodA gene sequence from Macrococcus 
caseolyticus was set as the outgroup. The whole genome sequences of S. schleiferi isolated from 
humans: 191, 192, 196, CDC: 132-96, CDC:78-04 and ATCC 43808T have been deposited at 
DDBJ/ENA/GenBank under the accession PNRJ00000000, POVG00000000, POVH00000000, 
POVI00000000, POVJ00000000 and POVK00000000 respectively. The Staphylococcus 
schleiferi 191, 192, 196, CDC: 132-96, CDC: 78-04 and ATCC43808 versions described in this 
paper are version PNRJ01000000, POVG01000000, POVH01000000, POVI01000000, 




Mevalonate and phosphomevalonate were shown to have a much higher pool-size in the 
S. aureus strains than either S. schleiferi or S. pseudintermedius (the smallest fold change being 
about 40 for mevalonate and 1022 for phosphomevalonate). Additionally, the mevalonate 
intensities for S. schleiferi and S. pseudintermedius are close the value for the media blank ≤ 2.8 
× media blank before normalization). Given this significant pool size difference, it seems that the 
S. aureus strains may be using mevalonate metabolically and the other strains are not. Since the 
main known metabolic role for mevalonate is isoprenoid synthesis, we postulate that isolates S. 
aureus USA300 and ST398 are using the mevalonate pathway for isoprenoid synthesis and 
strains S. schleiferi 196, 192, 132-96, 182150, 182116, and S. pseudintermedius 06-3228 are 
using the non-mevalonate pathway. These are the expected pathways for these species based on 
previous literature.133 
Based on the metabolic pathway reconstructions from KEGG and MicroCyc, the canine 
staphylococcal isolates (S. pseudintermedius HKU10-03, S. schleiferi 1360-13, S. schleiferi 
2142-05 and S. schleiferi 5909-02) clustered closely together. In contrast, all human S. schleiferi, 
S. schleiferi TSCC54 and S. schleiferi 2317-03 are segregated suggesting they have a unique 
metabolic profile as shown in k and g clusters (Figure 2-6). S. lugdunensis HKU09-01, S. aureus 
subsp. aureus COL and S. epidermidis RP62A were found to use the mevalonate pathway for 
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Figure 2-6. Clustering Heat Map of Staphylococcus Isolates. A hierarchical clustering 
heat map of differentially abundant subsystems among S. schleiferi and other 
staphylococcal species. The top dendrogram shows the relationship between S. 
schleiferi and other staphylococcal species based on subsystems profile similarity. 
 
 




Figure 2-7. Staphylococcus Phylogenetic Tree. A Neighbour-Joining phylogenetic tree constructed from the Staphylococcus 
superoxide dismutase gene (sodA) is shown. The numbers indicate substitutions per site. 
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isoprenoid biosynthesis whereas, S. pseudintermedius HKU10-03 and all S. schleiferi strains 
examined use the non-mevalonate pathway (2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-
xylulose 5-phosphate (MEP/DOXP) pathway) as an alternative method for isoprenoid 
biosynthesis. This is based on their genomes and is consistent with metabolomics results. 
In this study, different species in the Staphylococcus genus were shown to utilize 
different isoprenoid biosynthesis pathways, which is in agreement with the Misic et al. 
findings.134  Furthermore, all of S. schleiferi isolates (human and canine) tested in our study were 
found to use the non-mevalonate pathway as their method for isoprenoid biosynthesis. Mammals 
use the mevalonate pathway to produce isoprenoids, and therefore the potential of antibiotics to 
treat bacteria by blocking the mevalonate pathway is precluded. However, for S. schleiferi or S. 
pseudintermidus infections, the non-mevalonate pathway is a ready target. Indeed, fosmidomycin 
has been used in veterinary medicine to treat staph infections in animals by blocking the non-
mevalonate pathway.121 This is not used for human Staphylococcus infections due to the 
prevailing understanding that almost all staph infections are due to S. aureus. However, these 
findings demonstrate that in pathogenic S. schleiferi and S. pseudintermidus isolated from 
humans fosmidomycin is in fact a viable treatment option. This should prove especially useful 
against drug-resistant strains like the already reported methicillin-resistant Staphylococcus 
schleiferi.121 A hierarchical clustering grouped canine staphylococcal isolates (S. 
pseudintermedius HKU10-03, S. schleiferi 1360-13, S. schleiferi 2142-05 and S. schleiferi 5909-
02) more closely together. In contrast, all human S. schleiferi, S. schleiferi TSCC54 and S. 
schleiferi 2317-03 have a unique metabolic profile and share some metabolic pathways with 
staphylococcus species found across human and animal hosts suggesting this is a part of human 
S. schleiferi host specialization. Applying comparative genomics, two complete prophages were 
identified in human S. schleiferi. Staphylococcus prophages may play an essential role in the 
development of bacterial strains and are crucial for the emergence of new virulent S. 
schleiferi lineages.  
 
Conclusions 
This experiment utilized semi-targeted metabolomics to elucidate the isoprenoid 
biosynthetic pathway in Staphylococcal isolates. Comparative genomics was also performed on 
various isolates of Staphylococcus, identifying the isoprenoid synthesis genotype, and shedding 
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more light on the relevance of genetic features such as prophages. Most staphylococcal research 
has focused on determining the extent of the danger posed by S. aureus and the development of 
new treatments for S. aureus infections. However, other species of staphylococci such as S. 
schleiferi, pose a threat to human health and are likely underdiagnosed. The goal of this work 
was to increase our understanding of S. schleiferi metabolism and facilitate future treatment 
options. The genetic and metabolomic data support each other to accomplish this goal. This 
information should help guide clinical practice as strains that use the non-mevalonate pathway 
(which all S. schleiferi and S. pseudintermedius used) are susceptible to the use of fosmidomycin 
as an antibiotic. This genomics data should support the research community in other ways as 
well, such as facilitating identification of pathogenic potential and genetic relatedness of these 
isolates with S. schleiferi isolated from dogs and supporting studies of other bacteria at the 
genome level. Additionally, it is hoped that this genetic data will support the eventual 
development of an effective vaccine against staphylococcus infections. 
This experiment demonstrates the complementary effect of using multiple omics 
techniques to build a picture of bacterial physiology and pathology. It is worth noting that the 
particular combination of metabolomics with genomics was not necessary. Metabolomics 
combined with proteomics or transcriptomics would also have been successful in characterizing 
isoprenoid biosynthesis. Whatever the combination, however, by mixing techniques and 
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Chapter 3: Metabolomics Advanced: An examination of simultaneous extractions 
for multi-omic analyses 
 
Introduction 
While metabolomics itself can be a useful tool, more often these studies are better when 
integrated with other techniques. One example has already been given in chapter 2. In that study, 
genomics and metabolomics were used complementarily to investigate the metabolic pathways 
of Staphylococcus isolates. These approaches are becoming more common and various 
combinations of genomics, transcriptomics, proteomics, metabolomics, and lipidomics show up 
throughout the literature.135-136 Often in these omic studies, sample preparation and extraction is 
one of the most labor-intensive steps. Performing one extraction across multiple samples can be 
very time consuming, and this is greatly increased if multiple extractions are performed to 
capture different classes of molecules. Additionally, if extractions are not performed on the same 
sample at the same time, variations in the physiological state inevitably occur. This is especially 
true for the metabolomics fraction as the metabolite profile can remarkably change in a matter of 
seconds.137 In the case of limited sample amounts (common with clinical experiments), being 
frugal with sample use is critical. And in some cases (such as tissue biopsies), it is impossible to 
get more than one sample from the same individual with the same composition (or in the case of 
continuous studying without killing the individual). For these reasons, if multiomics (such as 
metabolomics, lipidomics, and proteomics) is employed, a method for the simultaneous isolation 
of each fraction is extremely desirable. In this chapter, two multiomics extraction methodologies 
and two lysis procedures are compared and evaluated for extraction efficacy of lipids, proteins, 
and metabolites. 
Chloroform, methanol, and water extractions are commonly used for both lipidomics and 
metabolomics.47, 51, 55-58 This is a biphasic extraction that can be conveniently adapted for the 
collection of both metabolites and lipids. Similar extractions are also used in proteomics 
preparations to purify proteins and wash out contaminates.138 This has been used occasionally for 
the preparation of multiple omics analyses as a concerted extraction.139-141 One paper in 
particular used this for the co-isolation of metabolites, lipids, and proteins, the so-called MPLEx 
method (metabolite, protein, and lipid extraction).61 Having been extensively tested for 
metabolites and lipids in very similar methods previously, the authors focused their validation on 
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the protein analysis and found that although MPLEx resulted in less than one third of the total 
protein content compared to a control method, they detected approximately the same number of 
peptides and proteins in their proteomic analysis, and concluded the method was viable for 
multiomic experiments. 
There is another method that has been used for simultaneous extractions. This is a 
method similar in principal to CME but employing methyl-tert-butyl ether (MTBE) instead of 
chloroform. This has the immediate advantage of avoiding a probable human carcinogen in the 
extraction solvent. This originated in a paper by Matyash et al. regarding a lipid extraction 
procedure that was more convenient than CME since MTBE is less dense than water and the 
organic phase forms the top layer.62 This also precipitates protein at the bottom of the vial, 
simplifying fraction collection. Matyash concluded that this method was at least as effective as 
Folch’s CME lipid extraction. This was adapted by Coman et al. as a method entitled: 
Simultaneous Metabolite, Protein, Lipid Extraction (SIMPLEX).60 SIMPLEX was found to 
perform similarly to a control experiment for phosphoproteomics and to give good results for the 
lipid analysis. The metabolite analysis showed moderately lower intensities as compared to the 
control and slightly higher relative standard deviations (RSDs). Despite slight drawbacks, the 
authors concluded that SIMPLEX is a viable option. Although both these methods, MPLEx and 
SIMPLEX, were tested against dedicated single extractions (the control groups), there has not 
been a direct comparison of different multiomic extraction methods to date.  
Both SIMPLEX and MPLEx employ sonication as a cell lysis step. Lysis is a very 
important part of any extraction to ensure complete extraction and metabolic quenching. 
Sonication is an aggressive lysis method that does ensure cell lysis, but results in sample heating 
and may cause metabolite degradation, especially since the sonication is typically not done with 
a high organic solvent composition and, therefore, may retain enzyme activity. Other lysis 
methods have been used as well, including acid, freeze-thaw cycles, high organic solvents, or 
some combination of these. These different procedures have generated conflicting results and 
clarifying what methods are effective for maximum extraction with minimal degradation will 
help guide future experimentation. 
Pseudomonas putida was used as the test organism in this project. Strain KT2440 was 
used, which is a plasmid-free version of a toluene-dregading P. putida strain isolated from a field 
in Japan and is the best characterized saprophytic Pseudomonad.142-143 This is an exciting 
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bacterium because of its remarkable potential for bioremediation. Indeed, studies have 
demonstrated the viability of P. putida for bioremediation of diverse pollutants such as 
petroleum, organophosphates, inorganic cyanides, organic solvents, and halocarbons.144-147 This 
also could serve as a model organism, as a safer version of the related Pseudomonas aeruginosa 
a human pathogen, which causes 10% of nosocomial infections.148 
To guide future multiomic experiments, a comparative study is needed that directly 
relates and details the strengths and weaknesses of each method. Here a CME multi-omic 
extraction as well as an MTBE multi-omic extraction were performed to directly compare these 
methods for multiomic analyses. Additionally, the lysis technique was also examined, testing a 
CME sonication (CME-S) method and a CME freeze-thaw (CME-F) method to understand the 
effects of lysis techniques on biomolecule extraction fidelity. This sets up two binary 
comparisons where MTBE can be easily compared to CME-S and CME-S can be compared to 
CME-F. Unfortunately, due to the COVID-19 lab shutdown during the latter phase of these 
experiments, we were not able to as thoroughly validate the LC-MS data as desired. However, 
the goal is not to perform a comparative discovery metabolomics experiment, but rather to test 
multiomics extraction procedures for viability. Simply testing if lipids, proteins, and metabolites 
can be simultaneously extracted does not require optimized analysis methods. Similarly, some 
rough comparisons should be able to be performed between the three methods despite less than 
ideal replication and optimization, and further experiments can validate conclusions. 
 
Material and Methods 
Multiomic Extraction Procedures 
Three different extraction procedures were tested. The first was a chloroform methanol-
based extraction with sonication (CME-S) performed similarly to methods common in the 
field.47, 51, 61 A cell pellet was resuspended in 1mL of PBS by vortexing. Two 500 μL aliqouts of 
this suspension were taken as two aliquots and centrifuged at 10,000 × g for approximately 3 
minutes to produce two samples with identical biological composition. The supernatant was 
discarded and to each pellet was added 140 μL of methanol and of water. The cells were 
suspended and lysed by tip ultrasonication for 5 minutes (with a 10 seconds on, 10 seconds off 
cycle for a total time of 10 minutes). Following lysis, 280 μL of chloroform were added, the 
mixture was vortexed and placed on ice in an orbital shaker for 1 hour and 20 minutes to extract 
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and partition analytes. The tubes were then centrifuged at 10,000 × g for 15 minutes to induce 
phase separation and the fractions were collected (the aqueous top layer, organic bottom layer, 
and insoluble material (proteins) in the center.) The water layer regained turbidity over time, and 
in certain cases additional centrifugation was performed before LC-MS analysis. 
A variant of this was also performed with freeze-thaw lysis instead of sonication (CME-
F). In this case, cells were split and collected as in CME-S, but chloroform and methanol were 
added with volumes of 280 μL and 140 μL respectively. After resuspension via vortexation, 
these were then flash frozen in liquid nitrogen and allowed to thaw on ice. After thawing, tubes 
were vortexed to disperse the cellular material. This was performed twice more for a total of 
three cycles. Following freeze-thaw lysis, 140 μL of water were added, the solution was 
vortexed, and placed in ice on an orbital shaker to extract and partition. The extracts were then 
centrifuged and collected according to the CME-S method. 
A third method was also tested using methyl-tert-butyl ether (MTBE) instead of 
chloroform. This is based on the Matyash et al. lipid extraction procedure, which has also been 
used for multiomic extractions.60, 62 This was performed identically to the CME-S method except 
125 μL of water, 150 μL of methanol and 500 μL of MTBE were added in the place of 
chloroform. Since MTBE is less dense than water, the organic phase was at the top and the 
insoluble protein was at the bottom of the vial. The MTBE fractions were dried under nitrogen to 
about half initial volume. 
 
Crude Protein Analysis 
The mass of the protein in the precipitated cell debris was measured using a Thermo 
Scientific Nanodrop spectrometer. The insoluble pellet was suspended through vortexing and 
was diluted by a factor of twenty before analysis with the spectrometer. The preprogrammed 
protein A205 Scopes method was used, which measures the protein concentration by measuring 
absorbance at 205 nm. The peptide bonds absorb strongly in the deep-UV, and this gives a 
method of quantification through the use of Beer’s law. Measurements were taken on three 
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Liquid Chromatography-Mass Spectrometry Analysis 
Metabolomic and lipidomic analyses were performed in technical duplicate using an LTQ 
(linear trapping quadrupole)-Orbitrap Velos Pro instrument coupled to an Ultimate 3000 LC 
system. The LC was operated in a split-flow nano LC method and interfaced with the Velos 
using a nano ESI source. Columns had an inner diameter of 100 μm and were packed manually 
using a pressure cell to a length of 15 cm using 5 μm ZIC-pHILIC (zwitterionic-polymer) 
particles. HILIC analyses of both metabolites and lipids were operated with a gradient of 100% 
B to 40% B over 20 min, followed by a return to the initial conditions and a wash/re-
equilibration for 15 min. Solvent B was 97% acetonitrile and 3% water with 5 mM ammonium 
acetate while solvent A was 100% water with 5 mM ammonium acetate. The use of HILIC 
avoids the issues RP has of extreme lipid retention and no retention of metabolites. The mass 
spectrometer was operated in a DDA mode with one orbitrap full scan followed by ten LTQ MS2 
fragmentation scans using CID at 35 normalized collision energy. For the lipid analyses, the 
scans were from 200 to 2000 m/z while the metabolite analyses were run from 50 to 1700 m/z. 




The data was analyzed using open source software mzMine.149 Features were detected 
from the raw data using MS/MS peaklist builder (with a 10 ppm tolerance), deisotoped, duplicate 
peaks filtered out, aligned in retention time, filtered according to their duration (0.1-8 min) and 
height (2e3 intensity), and finally were gap filled. After this processing, features were searched 
against online databases with a 10 ppm tolerance. Lipid Maps was used for the organic data, and 
Metacyc as well as MassBank and KEGG was used for the aqueous data.93-96 The samples were 
blanked by subtracting the blank peak area from that of its corresponding samples. Following 











Lipid samples (organic fractions) were run on the HILIC LC-MS method in both positive 
and negative mode. This ensured good coverage of different lipid classes which do not all ionize 
in the same mode. Phospholipids are polar enough to retain and be separated on HILIC columns. 
Non-polar/neutral lipids will most likely elute in the dead-volume, but these are not expected to 
ionize well in the ESI setup used. In this experiment, we focus on phospholipids which should be 
the most abundant and well represented by the experimental setup. 
The lipidomics base peak chromatograms (BPCs) for each extraction method are 
displayed to demonstrate the presence of analytes in the organic fraction for each extraction 
(Figure 3-1). Across all extractions, the positive mode runs showed more than an order of 
magnitude greater signal than the negative mode runs. Despite this, peak shapes are generally 
similar between modes. MTBE had the richest BPC with much of the signal spread out over 5 to 
10 min. The CME BPCs had different shapes than MTBE, though similar to each other. These 
had two peaks, one centered at 9 min and one at 14 min. Despite different signal intensities, a 
similar number of features were detected by mzMine. There were about one thousand features 
for each sample set in each mode. MTBE showed significant differences from its analogue 
CME-S in that more than half of the features detected in that pairing were specific to only one 
condition. CME-S and CME-F had much in common and slightly more features were detected 
with CME-F. 
The features were annotated by matching to the lipids maps database (searched with 10 
ppm mass accuracy) and the ID results are summarized in Table 3-1 and Figure 3-2. The total 
carbons for lipid tails range from 13 to 44 with degrees of unsaturation up to 8, with 0-2 being 
the most common.  
Phosphatidylserine (PS) was the lipid class with the greatest number of IDs. These were 
more commonly annotated in positive mode than in negative mode and range from 81 to 92 in 
positive mode and 67 to 77 in negative mode. Additionally, the peak area is 23-fold higher on 
average in positive mode compared to negative mode. 
The second most frequent class ID was phosphatidylcholine (PC) with up to 67 feature 
IDs. More PC was detected in positive mode than negative mode for MTBE, but more in 
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Figure 3-1. Lipidomic Base Peak Chromatograms. This BPC are shown for the organic 
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Table 3-1. Phospholipid Annotations by Sample. Each tentative annotation of a standard 















CL 30 12 22 9 16 16 
PA 12 24 10 22 16 26 
PC 62 65 56 55 67 60 
PE 2 5 1 5 4 5 
PG 6 46 6 40 6 46 
PI 5 5 2 5 5 6 




Figure 3-2. Lipid Class Annotation Bar Graph. Number of annotated features belonging 
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negative mode than positive mode for both CME methods. Despite this, these PC lipids were 
well over an order of magnitude more intense in positive mode than in negative mode. 
Phosphatidylglycerol (PG) was detected with up to 46 annotations in negative mode, 
however very few PG lipids were annotated in positive mode (6 in each sample). An example of 
a PG negative mode feature is shown in Figure 3-3, with fragmentation allowing tail lengths to 
be decerned. Cardiolipin (CL) was annotated more in the CME extracts than MTBE with 30 in 
CME-F, 22 in CME-S, and 16 in MTBE (all positive mode). Phosphatidic acid (PA) had about 
25 IDs in negative mode and 10 to 16 in positive mode with slightly more IDs in MTBE than in 
CME. There were very few phosphatidylethanolamine (PE) and phosphatidylinositol (PI) 
annotations with about 5 across the board for both. 
 A rough quantitative comparison of the method was performed by plotting a heatmap of 
the peak areas (relative to the mean) for all of the features with lipid annotations. This was done 
with the positive mode data as that gave the best signal and can be seen in Figure 3-4. The 
MTBE extraction gave greater yields overall, followed by CME-F and then CME-S. 
Average relative standard deviations (RSDs) of peak areas for features present in each 
replicate of an extraction were calculated for technical replicates and compared to the overall 
relative standard deviation to evaluate reproducibility. The MTBE method had average RSDs of 
46% for both sets of technical replicates and an overall RSD of 56%. CME-S gave technical 
replicate RSDs of 45% and 68%, but an overall deviation of 51%. CME-F gave technical 
replicate RSDs of 42% and 43%, but an overall deviation of 52%. These values were consistent 
with the negative mode data where MTBE gave technical RSDs of 48% and 56% and an overall 
RSD of 68%. CME-S gave technical RSDs of 49% and 44%, and an overall deviation of 49%. 
CME-F gave technical RSDs of 42% and 40% and an overall deviation of 51%.  
 
Proteins 
After protein quantification by nanodrop assay, the following data were obtained. The 
MTBE extracts gave 2.15 and 2.07 mg of total protein (a yield previously found to be 
approximately 10% of the starting cell pellet) while the CME-S gave 1.62 and 1.55 mg, and the 
CME-F gave 1.48 and 2.60 mg. It is of note that the different extraction methods gave 
qualitatively different protein precipitates. CME-S and MTBE gave protein precipitates that were 
 




Figure 3-3. Mass Spectrum of PG (34:2). The mass spectra for a Phosphatidyl glycerol (34:2) feature are given. The full scan 
(A) and tandem MS are shown (B). The parent mass is 745.51 m/z. The 267.21 and 478.33 peaks indicate the presence 
of an 18:1 tail, and the 253.19 suggests the presence of a 16:1 tail, supporting the 34:2 assignment.
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Figure 3-4. Lipid Heatmap. This displays the foldchange of the log-transformed peak 
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white and had a somewhat dry appearance while the CME-F was off-white or tan and had 
something of a slimy appearance.  
 
Metabolites 
The metabolite (aqueous) fractions were analyzed according to the same LC-MS 
procedure as the lipids except the preliminary negative mode data were poor and so positive 
mode was focused on for this study. Although RP may be included in future studies, HILIC is 
expected to perform better for the polar metabolites, as many metabolites will not be retained by 
RP and elute in the dead-volume. An ion-pairing reagent is disfavored from use which would 
improve retention but impede ionization, as both positive and negative mode data is desired (at 
least for the lipids). The BPCs can be seen in Figure 3-5, and they were all fairly comparable 
with small peaks between five and eighteen minutes and a large peak centered at fifteen minutes. 
The peak at fifteen minutes is primarily due to sodium acetate clusters. 
After processing data using mzMine with a 10 ppm mass tolerance, more than one 
thousand features were detected, the results of which are summarized in Figure 3-6. There are 
few differences in the features detected between the CME methods. However, the MTBE method 
and the CME-S method show a surprising amount of diversity in the features detected where 
more than half of the features are specific to an extraction method with more features detected in 
MTBE. 
Annotations of the features include a variety of different metabolites including amino 
acids, nitrogenous bases, and nitrogen metabolites, though there is a lack of central carbon 
metabolites. Examples include alanine, cystine, guanine, and urea. Many energy molecules were 
annotated, with many nucleotide phosphates throughout. These bear further consideration as they 
give a clue into the fidelity with which the extraction represents the metabolic state. Degradation 
is especially an issue for metabolomics. Limiting metabolite degradation is critical to capture an 
accurate picture of the cellular physiological state, but many of these are labile and can easily 
degrade, either abiotically, or through enzymatic action. The nucleotide phosphates are some of 
the most notoriously unstable metabolites and are the best choice to assess degradation. Those 
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Figure 3-6. Shared Metabolite Features in Extracts. This pie-chart breaks down the total 
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annotated in the feature list include ATP, CTP, CDP, CMP, GTP, GDP, GMP, UTP, UDP, and 
UMP. After further examination, the GXP group of nucleotide phosphates were shown to give 
the most reliable data, and so these were used to compare the extraction methods for degradation 
potential. Figure 3-7 demonstrates the GXP EICs for each set of samples. Note that the retention 
times increased slightly when going from GMP to GDP to GTP, as is consistent with increased 
hydrophilicity. GTP was not reproducibly detected in the CME-S extract (2 of 4 runs), but of 
those two runs, the GTP/GDP ratio was 4.09. For CME-F and MTBE extracts the ratios were 
6.35 and 3.51 respectively. GDP/GMP ratios followed a similar pattern with values of 0.339, 
1.88, and 1.26 for CME-S, CME-F, and MTBE respectively. 
 To provide a quantitative comparison of the feature intensities, a heatmap was generated 
comparing the foldchange of every feature in each sample relative to the mean. This can be seen 
in Figure 3-8. Blocks of features associated with different extraction methods, but none had 
clearly higher intensities globally. 
The reproducibility of the extraction was again estimated by comparing the RSDs of the 
technical replicates with the overall RSD. The MTBE extraction had technical RSDs of 39% and 
36% with an overall RSD of 45%. The CME-S extraction had technical RSDs of 36% and 39% 
with an overall RSD of 49%. The CME-F extraction had technical RSDs of 32% and 37% with 
an overall RSD of 42%. 
To determine how much lipid content was present in the metabolite fraction, the data 
were run in mzMine against Lipid Maps as the lipid fractions were. A moderate number of 
phospholipids were detected in the metabolomics samples with 1 PA, 20 PC, 4 PG, and 7 PS for 




The BPC for the MTBE fraction demonstrated good signal (at least in positive mode) and 
decent separation with signal spread across an eight-minute period (Figure 3-1). This is 
promising, demonstrating a good amount of analyte in the extract. The CME BPCs, on the other 
hand, show mostly a clump at 9 minutes (and at 14 min. for negative mode). Although there is 
still good signal, this means most analytes will be eluting at the same time, which may will 
hinder analysis through ion-suppression. Additionally, if too many analytes elute at the same 
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Figure 3-7. Extraction Ion Chromatograms of GXPs. The EICs for guanosine 
triphosphate (GTP), guanosine diphosphate (GDP), and guanosine 
monophosphate (GMP) are given for each extraction condition, A. MTBE, B. 






























































- 58 - 
 
 
Figure 3-8. Metabolite Feature Heatmap. This displays the foldchange of the log-
transformed peak areas for each metabolite feature relative to the mean. 
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 time, the DDA cycles may not be fast enough to select all analytes for fragmentation. The signal 
drop seen in both the BPC and the average peak areas from positive to negative mode is 
intriguing and could be due to differential ionization efficiencies of the lipids. Overall, the BPCs 
are promising and display what seems to be a successful extraction of lipids. 
Looking at the annotations may reveal more about the extraction efficacy. PS was the 
most annotated lipid, with large numbers of the species detected. The PS annotations 
demonstrate an ionization preference for positive mode based on peak area. This is a zwitterionic 
lipid and should ionize in both modes, so it is odd to see such a large increase in the peak area in 
positive mode. This could imply some technical difficulties with negative mode, such as a non-
optimized spray voltage. Regardless, large numbers are seen in both modes. This indicates PS as 
a major contributor to the lipidome; however, the presence of PS in such high numbers is 
surprising as PS is thought to be primarily an intermediate to PE and not a major membrane lipid 
in P. putida.150 While some of these extracted ion chromatograms are poor, others show decent 
peak shapes (Figure 2-9), so it appears these are real analytes. Since these are just tentative 
annotations, more verification of the IDs (including the use of standards) would help to shed 
light on the abundance of these components and the accuracy of these IDs.  
PC, with the second most annotations, is also a surprising ID for two reasons. First, large 
amounts are annotated in negative mode. Due to the quaternary ammonium in the PC headgroup, 




Figure 3-9. Extraction Ion Chromatograms for Two PS Lipids. This shows the EICs for 
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of M–2H ions in ESI, making ionization in negative ESI impossible without adducts, such as 
chloride. The database was not searched for adducts other than hydrogen (M±H), so the PC 
annotations in negative mode seem to be impossible. One explanation of this is that these are 
tentative annotations and could simply be incorrect. Another explanation exists, however, that 
these are not false, but rather mislabeled. PE differs from PC by only C3H6, which means a PE 
with n saturated carbons and a PC with n – 3 have identical masses. An examination of the 
literature shows that PC lipids are not believed to exist in P. putida KT2440, while PE is one of 
the more abundant phospholipids.151 Given that there are extremely few direct PE annotations in 
the data, mzMine seems to favor PC annotation even when these are nonsensical. Thus, these PC 
annotations are more likely to be PE with a net tail length three carbons greater. This assignment 
fits the data best, as PE can ionize in negative mode, but is more suited to positive mode. This 
helps explain the discrepancy between the BPC signal intensities as well as the increased peak 
area of the PC (PE) features in positive mode and its presence in negative mode. 
PS and PE, based on annotations, seem to be the largest contributors to the P. putida 
lipidome. Phosphatidylglycerol is the next greatest contributor. This is one of the main lipid 
classes expected to be present in P. putida.151 Based on annotations, this shows a strong 
preference for negative mode—which is consistent with the chemistry of the molecule. The 
intensity is low in general for these features. This may be due to poor ionization or just low 
abundance of PG lipids. 
Cardiolipin and phosphatidic acid also have minor contributions to the lipidome, while 
phosphatidylinositol seems to be negligible. Phosphatidic acid is also not expected to be a major 
membrane contributor and could be present merely as an intermediate in the synthesis of other 
phospholipids.151 Cardiolipin has been reported in P. putida before and is not a surprising ID.151 
The most cardiolipin IDs are in the CME-F (positive) data set followed by CME-S and MTBE. 
This may be due to the fact cardiolipins are larger lipids and more hydrophobic and chloroform, 
being the less polar solvent, may capture these better.152 
Overall, the three major lipid classes in P. putida, PE, PG, and CL, are observed, 
implying the extractions tested are viable options for bacterial lipidomics. More examination is 
necessary to determine the source of the large amount of unexpected PS lipids. Slight differences 
in the lipid profiles between MTBE and the CME methods were observed, but not enough to 
explain the large differences in the BPC profiles. Technical difficulties ought also to be 
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considered as they may play a role in the observed differences. The CME extracts were run at a 
later point with a different column than the MTBE samples. The column, although packed to the 
same length, had an extended section of unpacked tubing. This could have resulted in a retention 
time shift, as well as compacting the range of elution, which would explain the differences in the 
BPC. The intensity differences between ionization modes seem to be due in part to differential 
ionization of the lipids, but it could also be due to a lack of optimization of the negative mode 
ESI conditions. Perhaps the HPLC solvent additive could be altered to give superior ionization in 
negative mode. 
Comparing the two CME methods against each other, they had very similar BPCs for 
both modes with the exception that CME-S gives stronger signals than CME-F. This is to be 
expected if freeze-thaw does not lyse all cells, as the cell debris indicates, since intact cells will 
precipitate with the other cell debris and their lipids will be sequestered in the precipitate. 
However, after examining the feature annotations, CME-F consistently results in slightly higher 
total features, as well as annotations per class, than CME-S does. An examination of the peak 
areas of the heatmap in Figure 3-4 reveals that CME-F also gave greater average peak areas than 
CME-S does. Again, this is hard to resolve with the BPC, which shows greater signal for the 
CME-S than for the CME-F. Although degradation may be an attractive explanation because 
degradation would lower analyte peak areas while increasing those of degradation products, 
which may not be annotated by mzMine, this is not likely since degradation is uncommon for 
phospholipids. Perhaps there are components other than phospholipids that are contributing to 
the observed differences and are extracted more readily by the CME-S method. Further testing 
will be needed to verify this. Triacylglycerols (TAGs), however, were not detected and only a 
few diacylglycerols (DAGs) were detected (8 in positive more, 10 in negative), meaning DAGs 
and TAGs are not a significant part of these hypothetical other components. 
Although the system was not validated for quantitative evaluations, a rough analysis of 
the reproducibilities of the peak areas was performed for each sample set by calculating the peak 
area RSDs. Since biological variation is controlled by extracting from the same cell pellet, the 
variations should be limited to that generated in the extraction and the LC-MS system. The RSDs 
of the technical replicates should include only that deviation caused from the LC-MS system, 
and by comparing to the overall RSD, the relative contribution of the extraction procedure can be 
evaluated. The RSD for MTBE positive data overall was 56% while that of the individual 
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replicates were 46%. This indicates that the extraction procedure adds about 0.1 or 10% to the 
RSD, a little more than a one-fifth increase. This is a moderate increase that is not excessive. 
CME-S exhibited little to no increase and CME-F also had about a 0.1 or 10% increase as well as 
MTBE. For the negative mode data, MTBE had an increase of about 0.16 or 16% and CME-S 
again had little to no increase while CME-F increased by about 0.1 or 10%. Although MTBE had 
a somewhat higher RSD, these are all in the same range as the positive mode RSDs, and given 
the signal drop across modes, it is surprising that they are not worse than the positive mode 




All extracts gave copious amounts of protein that are more than sufficient for proteomic 
analyses. The physical differences observed in the lysates is relevant, however. Because the 
CME-F pellets had a more slimy and off-white appearance, this implies that the cells were not 
fully lysed by the freeze-thaw method, which could be represented in its inconsistent protein 
yield. To better characterize the extraction viability for protein analysis, the recovered protein 
should be analyzed through proteomics. However, that was beyond the current scope of this 
work, and future experiments hope to elucidate the relationship between solvent, lysis, and 
protein yield. This test shows that these methods extract sufficient protein for proteomic analysis, 
making these viable for proteomics as well as lipidomics with the possible exception of CME-F. 
It is worth noting that coupling this protein collection to a proteomics sample preparation method 
would be trivial. 
 
Metabolites 
To determine the efficacy of the extraction for polar metabolites, the BPCs for the 
samples were first examined. The large peak in the BPC was identified to be sodium acetate 
clusters by a repeating 82.0032 m/z unit (sodium acetate’s exact mass is about 82.0031 Da), see 
Figure 3-10. Acetate is present in the HPLC solvents, and the sodium is probably from residual 
PBS that was used to split the cell pellet. If a washing step is employed, or with harder 
centrifugation, the PBS could potentially be completely removed. However, washing may also 
lead to the leakage of metabolites. Beyond the large peak, there are smaller peaks in the 
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Figure 3-10. Spectrum Showing Sodium Acetate Adducts. This spectrum shows the repeating 82.0032 m/z peaks assigned to 
sodium acetate clusters. 
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chromatogram, which can be seen throughout. This indicates that the extractions are indeed 
successful in collecting metabolites. This is reinforced by the observation that mzMine annotates 
approximately one thousand features in each method, a rich enough data set. CME-S and CME-F 
have almost all of their features in common, whereas CME-S and MTBE share less than half of 
the unique features between the two. Potentially, this could be related to different selectivities of 
the solvents involved. The solvents were balanced such that an approximately equivalent amount 
of methanol and water were added in both the MTBE and the CME methods. So, differences in 
partitioning or extraction efficiency would result from the organic solvent. However, more, or 
different, features may not necessarily be a good thing. It may mean that analytes are spreading 
between both the organic and aqueous layers, thereby diluting the analytes and making the 
extracts unnecessarily complex. To help account for that, the annotated features were examined 
for commonalities with the organic fraction. MTBE had twice as many (16 more) phospholipid 
annotations after running through Lipid Maps as CME-S did. Some of these features may be 
related to lipids that do not fully partition into the organic layer. This implies the chloroform has 
superior performance in extracting lipids into the organic phase relative to MTBE. This 
performance difference is likely greater than it first appears, as there was approximately twice 
asmuch MTBE used in the extraction as chloroform, which ought to favor MTBE drawing more 
lipids out of the aqueous fraction. This differential extraction may be caused by MTBE’s greater 
polarity not extracting the lipids as efficiently as the chloroform-based solvent.152 To better 
characterize different extraction profiles, van Krevelen diagrams were generated using the Open 
van Krevelen software (Figure 3-11).103 These diagrams were generated with a 10 ppm tolerance 
and ions below 15% of the most intense ion were filtered to clarify the analysis. Based on the 
van Krevelen profiles, the extractions appear to have similar compositions.  
One factor that was particularly intriguing is whether the lysis method played a role in 
metabolite degradation. To assess this, the ratio of energy metabolites was calculated. The GXPs 
were chosen to highlight this comparison as they had the best quality data. That can be seen from 
the EIC as well as the accompanying spectra, a Full-Scan showing GMP as the most intense peak 
and a tandem MS showing a strong 152 m/z peak that fits a guanine fragment (see Figure 3-12). 
GTP/GDP and GDP/GMP ratios are good way to assess degradation because degradation will 
tend to drive those ratios down. Therefore, in general, the higher the ratios, the less degradation. 
Ratios of intracellular GTP/GDP vary depending on the source, but taking an average from three  
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Figure 3-11. van Krevelen Diagrams of Metabolomics Results. van Krevelen diagrams 
are shown for each of the extraction types. The x-axis plots the oxygen/carbon 
ratio and the y-axis plots the hydrogen/carbon ration. A. corresponds to CME-F 
data, B. corresponds to CME-S data, and C. corresponds to MTBE data.  
 






Figure 3-12. Spectra for Guanosine Monophosphate. The spectra for GMP in the CME-S 
extract is shown. A shows the full-scan where CMP is the base peak and B shows 
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different sources gives a value of 7.5.35, 153-154 This is moderately close to the value obtained for 
the freeze-thaw method (about a 15% difference). CME-S was different from the literature value 
by 46% and MTBE by 53%. The GDP/GTP ratio averaged from two sources is 2.92 this gives 
percent differences of 36%, 88%, and 57% for CME-F, CME-S, and MTBE respectively.35, 154 
The ratios demonstrate that CME-F preserves high energy molecules the best with a low percent 
error relative to a literature average (and the ratio actually exceeded that of one of the 
citations).35 Additionally, MTBE may perform slightly better than CME-S as GTP was not 
reproducibly detected in CME-S and the GDP/GMP ratio was higher for MTBE. It is not 
surprising that the sonication lysis would perform worse than the freeze-thaw, as during 
sonication the sample sits at room temperature for a lengthy preprocess, which can itself cause 
significant local heating. With the freeze-thaw method, the solution stays at or below 0 °C 
throughout the lysis process. Although unclear, the prospect of MTBE limiting degradation more 
than CME-S is surprising, and it would be very interesting to test an MTBE-freeze-thaw 
extraction to more conclusively determine if the solvent plays a role in metabolite degradation. It 
is worth noting, that it is possible these differences could also be due to changes in the extraction 
efficiency and not necessarily degradation. 
The reproducibility was again not greatly affected by the extraction procedure with 
increases in RSDs of about 7.5% for MTBE, 11.5% for CME-S, and 7.5% for CME-S. The 
MTBE method is again more similar to the CME-F than the CME-S although the procedure is 
more similar CME-S. This could mean that both the use of MTBE over chloroform and the use 
of a freeze-thaw lysis over sonication individually improve results. A freeze-thaw lysis with 
MTBE solvent would be an illuminating companion experiment to investigate what solvent 
effects may be present. 
 
Conclusions and Future Directions 
Returning to the fundamental goal of this experiment, are these extractions successful for 
the simultaneous extraction of lipids, proteins, and metabolites? Despite ways to improve the 
analysis, the answer appears to be yes. Lipid fractions show good BPC signals and rich numbers 
of features, protein analysis reveals abundant protein yields, and although the metabolite analysis 
leaves room for improvement in terms of overall signal and certain IDs, identifications do  
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include important and challenging metabolites such as high energy nucleotide phosphates. This 
corroborates the previous evidence in the literature about the effectiveness of these extraction 
methods.60-61  
The second goal was to compare the different solvents and lysis methods against each 
other to test differential extraction efficiencies. Overall, these three different methods behave 
fairly similarly while the CME methods may give cleaner extracts based on lipid presence in the 
aqueous fraction. CME-F yields the best GTP/GDP and GDP/GMP ratios, with MTBE slightly 
better than CME-S. MTBE also saw larger peak areas for lipidomics following by CME-F, then 
by CME-S. suggesting the best method may in fact be a MTBE freeze-thaw method; however, 
particularly for proteomics, more tests should be done to determine if inadequate lysis with 
freeze-thaw is an issue. One other factor to consider is the convenience between chloroform and 
MTBE. Although similar methods, MTBE simplifies fraction collection slightly by pelleting the 
proteins on the bottom of the centrifuge vial. Additionally, MTBE is not a probable carcinogen 
as opposed to chloroform, which is a marked improvement from a safety perspective. Therefore, 
although further experimentation is needed to validate findings, based on these preliminary 
results, the MTBE extraction procedure is recommended out of the three tested for multiomic 
extractions. 
There are various avenues for future research to improve on this study and more 
rigorously validate observations. Although samples were run with duplicate extractions and 
duplicate technical replicates, for a total of four runs per extraction, this is a relatively small 
sample size and performing the same experiment with triple or quintuple replicates would be an 
easy way to generate more meaningful data. As previously mentioned, it is unclear if the PS 
annotations are accurate as these are surprising to find in a P. putida extract. Using PS standards 
and probing the tandem mass spectral data more deeply should help to clarify this. Also, lipid 
features can be investigated more fully for components other than phospholipids, which may 
help clarify the source of the signal discrepancies between CME-F and CME-S. Further 
optimization of the LC-MS method will also add needed rigor to the comparisons particularly the 
quantitative ones such as the GXP ratios and heatmaps. Finally, the database annotations by 
mzMine deserve further investigation. There are several features with poor extracted ion 
chromatograms, calling into question the existence of those features. Also, multiple features will, 
at times, share identifications, an issue that, again, could be solved by standards and further MS2 
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investigation. Despite definite room for improvement, this is a foundational experiment that can 




In chapter 1, metabolomics was discussed and put into context with other omic 
techniques. The various challenges of other omics and the incomplete physiological picture they 
give were discussed as reasons for pursuing metabolomics. Metabolomics is open to the same 
criticisms, however. The experimental protocols are not well established and harder to perform 
than proteomics or genomics. The informatic backend is even further behind the experimental 
side. Biological interpretation is often harder than other omics despite being closer to the 
phenotype (compared to genomics or transcriptomics), as separating signal from noise, artifact 
from critical feature is extremely challenging. Additionally, there is not always a good way to fit 
together metabolomics results to form a clear biological picture. In chapters 2 and 3, however, 
metabolomics has been described as it fits in relation to other omics experiments. By stacking the 
analyses, outliers can be sorted out, physiological differences can be exposed, and observations 
confirmed or corrected. This is the future of metabolomics. This is the future of all omics and 
systems biology, the integration of multiple complex analyses to yield a web of data that can be 
teased apart to elucidate the chemical underpinnings of life. 
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Table A-1. Staphylococcus Metabolites Normalized 196, 192, 06-3228. This table lists the normalized intensities associated 
with metabolite annotations for strains 196, 192, and 06-3228. 196_1 had an optical density of 0.402, 196_2 had an 
optical density of 0.415, 196_3 had an optical density of 0.470, 192_1 had an optical density of 0.434, 192_2 had an 
optical density of 0.447, 192_3 had an optical density of 0.445, 06-3228_1 had an optical density of 0.338, 06-3228_2 
had an optical density of 0.349, and 06-3228_3 had an optical density of 0.337. 
 
COMPOUND 196_1 196_2 196_3 192_1 192_2 192_3 06-3228_1 06-3228_2 06-3228_3 
Dimethylglycine 4.6E+07 4.2E+07 7.0E+07 3.1E+07 2.1E+07 4.4E+07 4.9E+07 6.7E+07 5.8E+07 
hydroxybutyrate 1.9E+08 2.3E+08 1.9E+08 1.8E+08 2.6E+08 3.4E+08 2.8E+08 2.4E+08 2.7E+08 
Histamine 8.7E+03 2.8E+04 2.1E+04 8.6E+03 9.9E+03 1.2E+04 4.5E+04 3.2E+04 4.8E+04 
Proline 1.1E+08 1.3E+08 1.1E+08 6.2E+08 6.3E+08 4.5E+08 8.3E+07 6.7E+07 7.5E+07 
Fumarate 7.0E+06 6.5E+07 1.3E+07 4.2E+07 3.5E+07 3.7E+07 1.6E+07 1.6E+07 1.6E+07 
2-Oxoisovalerate 1.1E+06 1.1E+06 1.2E+06 2.4E+06 4.0E+06 5.3E+06 6.7E+06 9.6E+06 4.9E+06 
Valine/betaine 5.3E+08 8.9E+08 6.1E+08 2.2E+08 3.1E+08 6.5E+08 5.3E+08 5.0E+08 4.6E+08 
Succinate/Methylmalonate 1.4E+09 2.1E+09 1.5E+09 9.5E+08 1.4E+09 2.3E+09 1.6E+09 1.5E+09 1.7E+09 
3-Hydroxyisovalerate 1.7E+08 1.5E+08 1.8E+08 3.4E+08 5.1E+08 6.7E+08 4.7E+08 4.4E+08 4.3E+08 
Homoserine/Threonine 5.3E+07 5.9E+07 5.1E+07 1.5E+08 2.1E+08 2.9E+08 2.0E+07 1.5E+07 2.1E+07 
3-Methylthiopropionate 3.6E+05 3.1E+05 2.1E+05 1.6E+06 1.9E+06 2.7E+06 2.7E+06 2.5E+06 2.7E+06 
Cysteine 1.1E+06 2.0E+06 1.3E+06 7.1E+05 1.3E+06 2.3E+06 6.5E+05 5.8E+05 7.7E+05 
Citraconate 1.9E+07 3.1E+07 1.8E+07 1.7E+07 2.5E+07 4.7E+07 2.3E+07 2.2E+07 1.7E+07 
N-Acetylputrescine 2.7E+05 6.2E+05 3.5E+05 4.9E+06 5.0E+06 5.2E+06 2.4E+05 2.0E+05 2.2E+05 
Hydroxyproline 7.2E+07 8.5E+07 9.0E+07 1.2E+08 1.2E+08 1.1E+08 1.9E+07 1.7E+07 1.6E+07 
Leucine/Isoleucine 3.1E+09 5.2E+09 3.5E+09 2.4E+09 3.1E+09 6.0E+09 2.7E+09 2.7E+09 2.3E+09 
methyl succinic acid 9.9E+07 1.3E+08 1.2E+08 6.2E+07 7.9E+07 1.2E+08 6.9E+07 6.8E+07 7.6E+07 
Asparagine 7.4E+08 8.4E+08 7.4E+08 2.8E+08 3.5E+08 5.0E+08 9.8E+08 9.4E+08 8.2E+08 
Hydroxyisocaproic acid 3.5E+08 3.6E+08 3.7E+08 1.5E+09 2.7E+09 3.4E+09 2.4E+09 2.4E+09 2.3E+09 
Ornithine 2.7E+08 2.6E+08 2.6E+08 4.1E+07 4.7E+07 6.1E+07 5.2E+07 5.1E+07 5.2E+07 
Aspartate 2.4E+09 3.0E+09 2.8E+09 2.7E+09 3.0E+09 4.1E+09 2.0E+09 2.0E+09 1.6E+09 
Homocysteine 7.3E+05 1.0E+06 6.3E+05 5.0E+05 5.2E+05 5.7E+05 2.7E+05 2.7E+05 2.7E+05 
Anthranilate 9.9E+06 8.7E+06 1.2E+07 1.1E+07 1.0E+07 9.1E+06 7.2E+06 7.0E+06 7.5E+06 
Hypoxanthine 9.5E+07 2.3E+08 1.1E+08 9.1E+06 1.5E+07 5.0E+07 5.9E+07 5.5E+07 5.7E+07 
Salicylate 5.3E+07 4.5E+07 6.5E+07 4.3E+07 3.6E+07 2.8E+07 2.8E+07 2.9E+07 2.6E+07 
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Table A-1. Continued. 
COMPOUND 196_1 196_2 196_3 192_1 192_2 192_3 06-3228_1 06-3228_2 06-3228_3 
Hydroxybenzoate 2.7E+07 2.8E+07 3.0E+07 3.1E+07 3.0E+07 2.8E+07 1.4E+07 1.5E+07 1.4E+07 
alpha-Ketoglutarate 1.6E+07 1.9E+07 2.5E+07 3.2E+07 7.3E+07 1.1E+08 1.5E+07 1.0E+07 1.3E+07 
Glutamine 2.7E+08 2.7E+08 3.1E+08 3.8E+08 3.8E+08 3.4E+08 1.4E+08 1.3E+08 7.9E+07 
Lysine 2.5E+07 3.5E+07 2.6E+07 2.9E+07 3.6E+07 4.8E+07 4.3E+07 4.4E+07 3.1E+07 
O-Acetyl-L-serine 1.4E+07 1.4E+07 1.2E+07 3.1E+06 4.3E+06 2.0E+06 6.9E+06 6.2E+06 4.1E+06 
Glutamate 2.6E+09 3.1E+09 2.8E+09 2.0E+09 2.7E+09 3.2E+09 1.5E+09 1.5E+09 1.1E+09 
Methionine 1.7E+08 3.5E+08 1.8E+08 1.1E+08 1.7E+08 4.3E+08 2.3E+08 2.1E+08 1.9E+08 
Guanine 1.8E+07 3.9E+07 2.1E+07 1.4E+07 2.3E+07 6.4E+07 2.1E+07 1.9E+07 1.8E+07 
Vanillin 9.1E+07 8.5E+07 8.9E+07 8.8E+07 7.9E+07 5.8E+07 8.5E+07 9.1E+07 1.0E+08 
Xylitol 1.3E+06 6.2E+06 2.3E+06 2.3E+06 3.7E+06 6.6E+06 6.6E+06 6.6E+06 9.1E+06 
Orotate 4.4E+07 8.6E+07 7.3E+07 3.0E+07 4.0E+07 1.1E+08 1.7E+07 1.4E+07 2.2E+07 
Dihydroorotate 1.9E+08 1.8E+08 1.6E+08 5.3E+06 8.2E+06 2.5E+07 1.1E+07 1.0E+07 1.1E+07 
pimelic acid 1.8E+07 1.9E+07 2.1E+07 1.4E+07 1.5E+07 1.5E+07 1.7E+07 1.8E+07 1.8E+07 
Indole-3-carboxylate 1.3E+06 1.2E+06 1.4E+06 1.5E+06 1.3E+06 1.3E+06 1.1E+06 9.7E+05 1.1E+06 
Phenylpyruvate 5.4E+07 4.1E+07 4.7E+07 4.9E+07 5.7E+07 4.0E+07 1.3E+07 8.9E+06 1.2E+07 
Methionine sulfoxide 8.2E+06 2.0E+07 1.1E+07 7.3E+06 1.0E+07 2.5E+07 1.4E+07 1.4E+07 1.3E+07 
Phenyllactic acid 1.1E+08 1.2E+08 1.3E+08 3.5E+08 4.5E+08 5.5E+08 2.1E+08 2.0E+08 2.0E+08 
Cysteate 1.2E+08 1.3E+08 1.5E+08 5.0E+07 5.3E+07 6.8E+07 3.1E+07 2.5E+07 3.3E+07 
Sulfolactate 4.9E+07 1.4E+08 6.9E+07 2.6E+07 4.4E+07 1.4E+08 8.8E+07 8.4E+07 8.0E+07 
D-Glyceraldehdye 3-phosphate 1.3E+07 1.9E+07 9.6E+06 3.1E+06 5.2E+06 1.3E+07 2.1E+08 3.5E+08 2.8E+08 
sn-Glycerol 3-phosphate 3.0E+07 1.0E+08 2.7E+07 1.2E+08 1.4E+08 5.2E+08 1.6E+09 1.9E+09 1.1E+09 
Aconitate 1.1E+08 1.9E+08 1.2E+08 1.1E+08 1.5E+08 2.9E+08 1.4E+08 1.4E+08 1.2E+08 
N-Acetylornithine 2.1E+08 2.5E+08 2.1E+08 4.0E+09 4.1E+09 4.0E+09 7.7E+07 8.4E+07 7.7E+07 
Citrulline 1.5E+09 1.3E+09 1.4E+09 9.1E+06 6.3E+06 1.1E+07 2.2E+08 2.0E+08 2.3E+08 
N-Carbamoyl-L-aspartate 9.2E+08 5.5E+08 7.3E+08 9.3E+06 1.5E+07 5.3E+07 1.9E+07 1.5E+07 1.8E+07 
Gluconolactone 1.6E+07 4.7E+07 2.1E+07 1.6E+07 2.2E+07 6.5E+07 2.4E+07 2.1E+07 2.3E+07 
Hydroxyphenylpyruvate 7.9E+06 5.4E+06 7.0E+06 3.8E+06 2.6E+06 2.3E+06 1.1E+06 1.1E+06 1.2E+06 
Tyrosine 3.7E+08 8.2E+08 4.8E+08 3.5E+08 4.7E+08 1.1E+09 5.0E+08 4.9E+08 4.8E+08 
Homovanillic acid (HVA) 1.1E+07 1.1E+07 1.0E+07 3.2E+07 3.8E+07 5.6E+07 2.4E+06 2.0E+06 3.6E+06 
Homocysteic acid 3.1E+07 3.4E+07 3.9E+07 2.1E+07 2.1E+07 2.0E+07 3.8E+07 3.1E+07 3.5E+07 
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Table A-1. Continued. 
COMPOUND 196_1 196_2 196_3 192_1 192_2 192_3 06-3228_1 06-3228_2 06-3228_3 
3-Phosphoserine 4.9E+06 6.7E+06 6.2E+06 1.7E+07 1.1E+07 1.3E+07 2.6E+06 2.4E+06 1.9E+06 
3-Phosphoglycerate 6.1E+08 6.7E+08 6.1E+08 6.6E+08 4.8E+08 4.5E+08 1.9E+09 2.2E+09 1.4E+09 
Acetyllysine 9.4E+07 1.1E+08 1.2E+08 6.1E+08 5.6E+08 4.6E+08 1.1E+08 1.2E+08 1.0E+08 
N-Acetylglutamate 3.2E+08 3.6E+08 3.7E+08 1.0E+08 1.4E+08 2.6E+08 1.7E+08 1.6E+08 2.0E+08 
homocitrulline 3.5E+07 3.4E+07 3.7E+07 2.9E+07 2.9E+07 3.0E+07 1.5E+07 1.6E+07 1.5E+07 
D-Gluconate 9.0E+07 1.7E+08 9.0E+07 4.6E+07 4.7E+07 1.1E+08 7.4E+09 8.1E+09 7.5E+09 
D-Glucarate 1.0E+06 4.3E+06 1.4E+06 4.8E+05 1.1E+06 5.8E+06 1.5E+06 1.4E+06 1.3E+06 
Jasmonate 4.5E+05 3.9E+05 5.9E+05 9.2E+05 1.0E+06 1.0E+06 3.7E+05 4.3E+05 3.4E+05 
Deoxyribose phosphate 8.6E+07 8.1E+07 6.9E+07 2.9E+07 2.6E+07 2.7E+07 2.5E+08 3.5E+08 1.1E+08 
Cystathionine 6.7E+07 5.4E+07 6.4E+07 1.8E+08 1.7E+08 1.3E+08 8.5E+06 8.6E+06 8.1E+06 
deoxycytidine 6.9E+06 1.2E+07 9.6E+06 1.7E+06 2.6E+06 4.8E+06 9.0E+06 8.3E+06 9.3E+06 
Ribose phosphate 5.6E+07 4.0E+07 2.8E+07 2.9E+07 3.7E+07 3.1E+07 6.6E+08 6.5E+08 5.8E+08 
Uridine 1.5E+07 1.9E+07 1.6E+07 7.0E+06 1.1E+07 2.0E+07 2.7E+07 2.3E+07 2.6E+07 
Shikimate-3-phosphate 2.5E+06 2.4E+06 2.8E+06 6.1E+04 1.2E+05 1.0E+05 2.0E+04 1.0E+04 0.0E+00 
6-Phospho-D-gluconolactone 1.6E+06 9.8E+05 7.6E+05 5.0E+05 7.4E+05 2.8E+05 3.9E+07 4.0E+07 4.0E+07 
Glucosamine phosphate 1.4E+07 1.0E+07 5.2E+06 2.0E+06 3.9E+06 1.7E+06 3.9E+07 4.4E+07 2.6E+07 
S-Ribosyl-L-homocysteine 5.8E+06 6.4E+06 5.4E+06 6.4E+05 8.1E+05 1.5E+06 4.4E+06 4.3E+06 4.2E+06 
6-Phospho-D-gluconate 8.9E+07 6.1E+07 3.9E+07 1.7E+07 2.4E+07 9.7E+06 1.6E+09 1.5E+09 1.3E+09 
Xanthosine 2.8E+06 2.5E+06 3.2E+06 1.5E+07 1.5E+07 1.2E+07 9.3E+06 7.7E+06 1.1E+07 
Ophthalmate 3.5E+05 1.2E+06 7.2E+05 6.3E+07 6.7E+07 6.9E+07 0.0E+00 0.0E+00 1.7E+04 
Sedoheptulose 1/7-phosphate 9.4E+07 6.6E+07 4.7E+07 8.4E+07 6.0E+07 5.1E+07 3.1E+08 2.8E+08 1.4E+08 
N-Acetylglucosamine 1/6-phosphate 1.2E+07 1.5E+07 1.1E+07 1.1E+07 1.1E+07 2.0E+07 3.7E+07 4.1E+07 3.0E+07 
Glutathione 3.8E+06 9.8E+06 5.2E+06 1.1E+07 1.2E+07 2.3E+07 3.2E+06 3.0E+06 3.4E+06 
IMP 3.8E+06 3.7E+06 3.1E+06 3.4E+06 6.1E+06 9.4E+06 3.9E+06 4.3E+06 3.6E+06 
Trehalose 6-phosphate 6.5E+05 1.6E+06 8.9E+05 9.2E+06 1.5E+07 1.8E+07 1.3E+07 1.3E+07 1.1E+07 
FMN 4.6E+06 4.8E+06 6.3E+06 3.7E+06 3.8E+06 3.8E+06 8.3E+06 8.6E+06 9.3E+06 
UDP-glucose 1.8E+08 2.4E+08 2.5E+08 3.5E+07 3.9E+07 4.7E+07 1.3E+08 1.5E+08 1.3E+08 
UDP-N-acetylglucosamine 5.5E+07 7.9E+07 8.4E+07 1.0E+08 4.8E+07 5.3E+07 5.9E+07 6.2E+07 5.7E+07 
NAD+ 1.8E+08 1.9E+08 1.9E+08 1.8E+08 1.8E+08 1.9E+08 1.4E+08 1.6E+08 1.4E+08 
NADH 3.0E+06 3.9E+06 4.3E+06 1.7E+06 1.6E+06 1.3E+06 5.4E+06 7.5E+06 5.3E+06 
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Table A-1 Continued. 
COMPOUND 196_1 196_2 196_3 192_1 192_2 192_3 06-3228_1 06-3228_2 06-3228_3 
Mevalonate 1.7E+07 2.6E+07 2.0E+07 9.2E+06 1.5E+07 2.8E+07 1.2E+07 1.1E+07 1.4E+07 
2-C-Methyl-D-erythritol 4-phosphate 1.8E+07 1.1E+07 2.0E+07 7.7E+06 7.5E+06 5.1E+06 1.6E+07 1.6E+07 1.4E+07 
Isopentenyl diphosphate 5.3E+06 2.1E+06 4.4E+06 1.5E+06 2.7E+06 4.2E+06 1.8E+06 5.4E+06 1.4E+06 
Geranyl diphosphate 4.2E+03 2.2E+03 4.5E+03 2.4E+03 0.0E+00 0.0E+00 1.9E+03 0.0E+00 0.0E+00 
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Table A-2. Staphylococcus Metabolites Normalized USA300, ST398, 132-96. This table lists the normalized intensities 
associated with metabolite annotations for strains USA300, ST398, and 132-96. USA300_1 had an optical density of 
0.459, USA300_3 had an optical density of 0.489, USA300_3 had an optical density of 0.439, ST398_1 had an optical 
density of 0.427, ST398_2 had an optical density of 0.401, ST398_3 0.435, 132-96_1 had an optical density of 0.367, 
132-96_2 had an optical density of 0.408, 132-96_3 had an optical density of 0.363. 
 
COMPOUND USA300_1 USA300_2 USA300_3 ST398_1 ST398_2 ST398_3 132-96_1 132-96_2 132-96_3 
Dimethylglycine 1.4E+08 1.6E+08 1.6E+08 2.0E+07 3.0E+07 1.9E+07 4.8E+07 6.1E+07 6.5E+07 
hydroxybutyrate 3.8E+08 3.6E+08 3.0E+08 9.4E+08 1.0E+09 9.8E+08 4.1E+08 6.1E+08 6.8E+08 
Histamine 6.9E+05 6.9E+05 5.9E+05 4.7E+05 4.8E+05 5.4E+05 3.7E+04 3.5E+04 1.2E+04 
Proline 2.9E+08 2.7E+08 2.5E+08 3.3E+08 3.3E+08 3.5E+08 6.1E+08 5.9E+08 4.4E+08 
Fumarate 1.2E+07 1.3E+07 1.4E+07 1.6E+07 1.5E+07 1.9E+07 2.3E+07 2.4E+07 1.9E+07 
2-Oxoisovalerate 9.9E+06 1.8E+07 1.7E+07 5.1E+06 5.1E+06 6.5E+06 2.9E+06 2.2E+06 1.7E+06 
Valine/betaine 1.1E+09 7.6E+08 6.6E+08 5.1E+08 7.3E+08 5.4E+08 3.9E+08 6.5E+08 8.4E+08 
Succinate/Methylmalonate 2.2E+09 1.5E+09 1.4E+09 2.0E+09 2.4E+09 1.9E+09 1.4E+09 2.2E+09 2.7E+09 
3-Hydroxyisovalerate 1.5E+08 1.2E+08 1.0E+08 1.6E+08 1.8E+08 1.6E+08 2.2E+08 2.6E+08 2.9E+08 
Homoserine/Threonine 4.9E+07 3.1E+07 3.1E+07 3.4E+08 3.9E+08 3.5E+08 2.2E+08 2.1E+08 1.5E+08 
3-Methylthiopropionate 4.7E+06 3.9E+06 3.3E+06 5.2E+06 6.3E+06 5.0E+06 4.1E+05 1.4E+06 1.8E+06 
Cysteine 5.8E+06 5.0E+06 4.0E+06 1.3E+06 1.6E+06 1.5E+06 6.8E+05 1.6E+06 2.6E+06 
Citraconate 2.4E+07 2.1E+07 1.6E+07 1.6E+07 1.8E+07 1.9E+07 2.7E+07 3.5E+07 4.9E+07 
N-Acetylputrescine 1.3E+06 6.6E+05 6.9E+05 1.4E+06 1.8E+06 1.5E+06 3.2E+06 3.7E+06 4.1E+06 
Hydroxyproline 3.3E+07 2.2E+07 2.0E+07 1.7E+07 2.4E+07 1.7E+07 7.9E+07 8.1E+07 8.0E+07 
Leucine/Isoleucine 6.3E+09 4.1E+09 3.7E+09 3.2E+09 4.5E+09 3.3E+09 2.9E+09 4.4E+09 6.1E+09 
methyl succinic acid  1.4E+08 1.4E+08 1.4E+08 1.4E+08 1.7E+08 1.3E+08 6.6E+07 1.1E+08 1.0E+08 
Asparagine 1.2E+09 1.1E+09 1.0E+09 1.3E+09 1.3E+09 1.3E+09 4.2E+08 5.9E+08 7.0E+08 
Hydroxyisocaproic acid 7.8E+08 6.5E+08 6.2E+08 6.9E+08 7.9E+08 7.5E+08 9.8E+08 1.1E+09 1.1E+09 
Ornithine 8.1E+07 9.2E+07 8.4E+07 1.7E+08 1.6E+08 1.8E+08 9.6E+07 9.0E+07 7.9E+07 
Aspartate 4.8E+09 5.0E+09 4.6E+09 3.8E+09 3.9E+09 4.2E+09 2.4E+09 3.0E+09 3.4E+09 
Homocysteine 8.4E+05 5.2E+05 4.2E+05 3.7E+05 4.9E+05 3.4E+05 9.6E+05 1.8E+06 2.2E+06 
Anthranilate 8.0E+06 1.0E+07 1.0E+07 1.1E+07 1.1E+07 1.3E+07 1.1E+07 9.6E+06 8.4E+06 
Hypoxanthine 2.0E+07 6.3E+06 5.7E+06 5.0E+06 1.2E+07 5.1E+06 1.1E+07 2.7E+07 4.1E+07 
Salicylate 2.5E+07 3.8E+07 4.1E+07 3.4E+07 3.3E+07 3.9E+07 3.3E+07 2.9E+07 2.2E+07 
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Table A-2 Continued. 
COMPOUND USA300_1 USA300_2 USA300_3 ST398_1 ST398_2 ST398_3 132-96_1 132-96_2 132-96_3 
Hydroxybenzoate 2.6E+07 2.8E+07 2.5E+07 3.1E+07 3.1E+07 3.0E+07 2.7E+07 2.5E+07 2.4E+07 
Acetylphosphate 2.3E+08 2.6E+08 2.6E+08 1.7E+08 1.5E+08 2.2E+08 7.9E+07 9.1E+07 8.2E+07 
alpha-Ketoglutarate 1.4E+08 1.9E+08 1.6E+08 8.3E+07 9.2E+07 1.0E+08 1.9E+08 3.0E+08 4.2E+08 
Glutamine 2.0E+08 2.2E+08 2.1E+08 1.4E+08 1.5E+08 1.6E+08 3.9E+08 3.6E+08 3.5E+08 
Lysine 6.5E+07 7.6E+07 7.0E+07 4.8E+07 4.7E+07 5.3E+07 3.7E+07 4.6E+07 5.2E+07 
O-Acetyl-L-serine 3.8E+06 3.8E+06 2.0E+06 1.3E+06 6.4E+05 1.8E+06 1.5E+07 2.0E+07 1.4E+07 
Glutamate 3.0E+09 3.1E+09 2.8E+09 2.8E+09 2.7E+09 3.0E+09 2.3E+09 2.8E+09 3.2E+09 
Methionine 5.0E+08 3.5E+08 2.9E+08 3.2E+08 4.1E+08 3.6E+08 1.6E+08 3.1E+08 4.7E+08 
Guanine 2.8E+07 9.1E+06 7.8E+06 7.6E+06 1.8E+07 8.3E+06 2.0E+07 4.6E+07 6.9E+07 
Vanillin 4.0E+07 6.6E+07 6.1E+07 5.4E+07 5.0E+07 5.8E+07 7.5E+07 6.3E+07 6.4E+07 
Xylitol 6.7E+06 3.2E+06 3.9E+06 4.0E+06 7.4E+06 3.8E+06 4.3E+06 9.4E+07 8.2E+06 
Orotate 1.2E+08 5.4E+07 4.4E+07 6.1E+07 1.1E+08 5.5E+07 3.8E+07 8.3E+07 1.4E+08 
Dihydroorotate 2.0E+07 8.9E+06 7.1E+06 1.9E+07 3.2E+07 1.3E+07 1.1E+07 2.5E+07 3.5E+07 
pimelic acid 2.0E+07 2.4E+07 2.3E+07 2.5E+07 2.6E+07 2.5E+07 1.4E+07 1.9E+07 1.6E+07 
Indole-3-carboxylate 1.4E+06 1.6E+06 1.5E+06 1.4E+06 1.5E+06 1.5E+06 1.2E+06 1.2E+06 1.1E+06 
Phenylpyruvate 1.2E+08 1.9E+08 1.6E+08 1.3E+08 1.1E+08 1.4E+08 7.9E+07 7.4E+07 5.6E+07 
Methionine sulfoxide 3.4E+07 1.5E+07 1.4E+07 1.1E+07 1.8E+07 9.9E+06 9.1E+06 1.9E+07 2.5E+07 
Phenyllactic acid 1.5E+08 1.3E+08 1.2E+08 1.8E+08 2.2E+08 2.0E+08 1.7E+08 2.0E+08 2.0E+08 
Cysteate 2.0E+08 2.6E+08 2.7E+08 1.6E+08 1.7E+08 1.6E+08 7.2E+07 7.7E+07 7.4E+07 
Sulfolactate 1.7E+08 1.0E+08 7.4E+07 1.6E+08 2.1E+08 1.7E+08 5.2E+07 1.2E+08 1.8E+08 
D-Glyceraldehdye 3-phosphate 2.1E+07 1.4E+07 1.8E+07 2.1E+07 3.9E+07 2.3E+07 5.2E+06 4.1E+07 5.7E+07 
sn-Glycerol 3-phosphate 1.4E+08 5.2E+07 5.5E+07 1.6E+08 1.9E+08 1.3E+08 4.4E+07 1.4E+08 1.3E+08 
Aconitate 1.5E+08 1.2E+08 1.0E+08 9.7E+07 1.2E+08 1.1E+08 1.6E+08 2.2E+08 2.8E+08 
N-Acetylornithine 2.1E+08 1.8E+08 1.8E+08 3.8E+08 3.9E+08 3.9E+08 2.8E+09 2.7E+09 2.8E+09 
Citrulline 3.8E+08 4.5E+08 4.1E+08 8.7E+08 8.1E+08 9.0E+08 2.9E+08 1.9E+08 8.9E+07 
N-Carbamoyl-L-aspartate 5.0E+07 2.9E+07 3.2E+07 1.2E+08 1.2E+08 1.1E+08 5.1E+07 9.2E+07 1.1E+08 
Gluconolactone 1.2E+08 8.1E+07 7.1E+07 3.3E+07 5.7E+07 3.3E+07 1.4E+07 3.8E+07 6.1E+07 
Hydroxyphenylpyruvate 9.7E+05 1.6E+06 1.7E+06 1.5E+06 1.4E+06 1.8E+06 2.0E+06 1.9E+06 1.2E+06 
Tyrosine 1.2E+09 8.6E+08 8.1E+08 6.3E+08 9.4E+08 6.7E+08 4.0E+08 7.6E+08 1.1E+09 
Homovanillic acid (HVA) 8.3E+06 5.7E+06 4.3E+06 8.1E+06 1.0E+07 6.7E+06 1.1E+07 1.8E+07 2.4E+07 
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Table A-2 Continued. 
COMPOUND USA300_1 USA300_2 USA300_3 ST398_1 ST398_2 ST398_3 132-96_1 132-96_2 132-96_3 
Homocysteic acid 2.3E+07 2.9E+07 3.3E+07 2.2E+07 2.1E+07 2.1E+07 1.0E+06 1.7E+06 2.4E+06 
3-Phosphoserine 9.6E+06 8.9E+06 9.5E+06 5.0E+06 5.7E+06 5.5E+06 7.3E+06 8.3E+06 8.9E+06 
3-Phosphoglycerate 1.9E+09 2.1E+09 1.7E+09 1.9E+09 1.6E+09 2.1E+09 4.6E+08 3.6E+08 3.3E+08 
Acetyllysine 3.2E+08 2.8E+08 2.9E+08 1.7E+08 1.9E+08 1.8E+08 7.6E+07 7.9E+07 8.0E+07 
N-Acetylglutamate 4.5E+08 4.4E+08 4.8E+08 4.6E+08 5.4E+08 5.3E+08 1.7E+08 2.6E+08 3.3E+08 
homocitrulline 4.2E+07 4.0E+07 4.3E+07 4.2E+07 4.2E+07 4.2E+07 3.9E+07 3.8E+07 4.3E+07 
D-Gluconate 1.3E+08 8.3E+07 8.6E+07 5.6E+07 8.4E+07 5.1E+07 6.3E+08 6.2E+08 5.4E+08 
D-Glucarate 7.0E+06 2.3E+06 1.9E+06 1.6E+06 4.3E+06 1.7E+06 8.9E+05 3.9E+06 7.8E+06 
Jasmonate 4.5E+06 8.8E+06 5.5E+06 4.1E+05 4.3E+05 5.5E+05 1.6E+06 1.7E+06 1.4E+06 
Deoxyribose phosphate 1.5E+08 9.6E+07 1.2E+08 6.6E+07 6.9E+07 6.5E+07 1.9E+07 2.3E+07 2.3E+07 
Cystathionine 1.4E+07 1.6E+07 1.7E+07 8.3E+06 8.1E+06 8.5E+06 1.0E+07 7.9E+06 7.3E+06 
deoxycytidine 1.9E+07 1.5E+07 1.5E+07 2.1E+07 2.7E+07 2.4E+07 6.8E+06 1.1E+07 1.7E+07 
Ribose phosphate 9.5E+06 7.9E+06 9.9E+06 6.0E+07 7.2E+07 6.5E+07 5.4E+07 8.6E+07 8.4E+07 
Uridine 1.1E+07 6.6E+06 5.1E+06 5.3E+06 8.3E+06 5.4E+06 1.0E+07 1.7E+07 2.2E+07 
Shikimate-3-phosphate 2.5E+04 3.4E+04 7.5E+03 2.8E+05 1.4E+05 4.1E+05 4.3E+05 3.2E+05 3.2E+05 
6-Phospho-D-gluconolactone 1.9E+05 1.4E+05 1.6E+05 9.2E+05 8.1E+05 1.4E+06 6.3E+06 4.7E+06 3.8E+06 
Glucosamine phosphate 1.2E+06 1.2E+06 1.6E+06 1.2E+07 1.1E+07 1.2E+07 1.2E+07 1.3E+07 1.2E+07 
S-Ribosyl-L-homocysteine 3.8E+06 3.0E+06 2.8E+06 3.4E+06 4.3E+06 3.7E+06 2.6E+06 3.9E+06 4.6E+06 
6-Phospho-D-gluconate 1.0E+07 1.0E+07 9.4E+06 3.1E+07 2.9E+07 4.6E+07 2.4E+08 2.6E+08 2.6E+08 
Xanthosine 7.4E+06 5.7E+06 5.8E+06 9.3E+06 9.1E+06 9.0E+06 9.0E+06 9.3E+06 6.9E+06 
Ophthalmate 1.7E+06 1.1E+05 5.2E+04 6.5E+04 9.9E+05 1.2E+05 1.3E+07 1.6E+07 2.1E+07 
Sedoheptulose 1/7-phosphate 1.5E+07 1.5E+07 1.5E+07 5.9E+07 6.4E+07 6.3E+07 9.1E+07 1.1E+08 9.7E+07 
N-Acetylglucosamine 1/6-phosphate 1.2E+07 6.6E+06 7.1E+06 1.2E+07 1.5E+07 1.3E+07 1.3E+07 1.3E+07 1.5E+07 
Glutathione 5.9E+07 5.6E+07 5.4E+07 5.0E+07 6.2E+07 5.5E+07 1.2E+07 2.0E+07 2.6E+07 
IMP 1.6E+05 1.3E+05 1.7E+05 4.2E+05 2.6E+05 4.2E+05 2.5E+06 1.8E+06 1.3E+06 
Trehalose 6-phosphate 2.5E+07 2.4E+07 2.3E+07 4.2E+07 4.7E+07 4.4E+07 9.3E+06 1.3E+07 1.3E+07 
FMN 2.9E+06 3.8E+06 3.7E+06 2.6E+06 3.1E+06 3.2E+06 2.5E+06 3.0E+06 3.1E+06 
UDP-glucose 6.8E+07 6.3E+07 5.9E+07 7.6E+07 9.1E+07 8.5E+07 3.7E+07 4.1E+07 3.9E+07 
UDP-N-acetylglucosamine 2.7E+07 2.1E+07 2.2E+07 7.5E+07 8.6E+07 8.9E+07 1.0E+08 4.9E+07 4.9E+07 
NAD+ 3.2E+08 3.6E+08 3.4E+08 2.8E+08 2.9E+08 3.3E+08 1.7E+08 1.8E+08 1.8E+08 
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Table A-2 Continued. 
COMPOUND USA300_1 USA300_2 USA300_3 ST398_1 ST398_2 ST398_3 132-96_1 132-96_2 132-96_3 
NADH 3.1E+06 3.5E+06 3.8E+06 9.2E+06 1.1E+07 9.1E+06 1.6E+06 1.4E+06 1.1E+06 
Mevalonate 1.8E+09 2.0E+09 1.5E+09 1.1E+09 1.3E+09 1.3E+09 1.4E+07 2.6E+07 4.5E+07 
2-C-Methyl-D-erythritol 4-phosphate 9.1E+06 1.8E+07 1.9E+07 1.5E+07 9.1E+06 1.4E+07 8.2E+06 7.2E+06 5.7E+06 
Isopentenyl diphosphate 2.5E+06 4.1E+06 4.1E+06 2.5E+06 7.8E+05 3.1E+06 2.1E+06 2.8E+06 1.9E+06 
Geranyl diphosphate 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 4.7E+03 0.0E+00 2.4E+03 
5-Phosphatomevalonate 8.6E+08 1.0E+09 9.7E+08 5.4E+08 5.7E+08 6.5E+08 7.5E+05 1.9E+05 4.0E+05 
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Table A-3. Staphylococcus Metabolites Normalized 182150, 182116, Blanks. This table lists the normalized intensities 
associated with metabolite annotations for strains 182150, 182116, and the blanks. 182150_1 had an optical density of 
0.439, 182150_2 had an optical density of 0.409, 182150_3 had an optical density of 0.479, 182116_1 had an optical 
density of 0.331, 182116_2 had an optical density of 0.338, 182116_3 had an optical density of 0.350. 
 
COMPOUND 182150_1 182150_2 182150_3 182116_1 182116_2 182116_3 MEDIA BLANK EXTRACTION BLANK 
Dimethylglycine 5.2E+07 6.8E+07 7.7E+07 7.6E+07 5.7E+07 8.0E+07 1.1E+06 6.5E+03 
hydroxybutyrate 2.0E+08 2.1E+08 1.9E+08 2.2E+08 2.0E+08 2.2E+08 5.3E+07 4.6E+07 
Histamine 3.1E+04 1.8E+04 8.9E+03 1.1E+04 1.7E+04 1.8E+04 0.0E+00 5.8E+02 
Proline 1.4E+08 1.7E+08 1.4E+08 1.1E+08 9.1E+07 9.9E+07 4.1E+07 3.0E+03 
Fumarate 6.8E+06 8.0E+06 9.9E+06 9.0E+06 9.1E+06 9.0E+06 3.1E+06 1.6E+06 
2-Oxoisovalerate 1.9E+06 2.8E+06 2.1E+06 2.1E+06 1.7E+06 2.1E+06 5.3E+06 1.9E+05 
Valine/betaine 7.1E+08 6.5E+08 6.9E+08 8.1E+08 5.8E+08 7.0E+08 3.6E+08 1.8E+04 
Succinate/Methylmalonate 1.7E+09 1.8E+09 1.9E+09 2.2E+09 1.8E+09 1.9E+09 1.2E+09 2.6E+07 
3-Hydroxyisovalerate 3.0E+08 3.5E+08 2.6E+08 3.2E+08 3.1E+08 2.8E+08 5.9E+07 8.4E+05 
Homoserine/Threonine 4.6E+07 5.2E+07 4.6E+07 2.9E+07 2.9E+07 3.0E+07 9.5E+07 8.7E+04 
3-Methylthiopropionate 1.8E+06 1.8E+06 1.7E+06 1.3E+06 1.4E+06 1.2E+06 4.0E+05 0.0E+00 
Cysteine 1.6E+06 1.2E+06 1.0E+06 2.6E+06 7.9E+05 3.4E+05 1.3E+04 7.7E+02 
Citraconate 1.7E+07 1.4E+07 1.7E+07 4.4E+07 2.6E+07 3.4E+07 6.4E+06 4.5E+05 
N-Acetylputrescine 3.4E+05 3.2E+05 3.3E+05 7.7E+05 3.7E+05 5.2E+05 6.4E+05 0.0E+00 
Hydroxyproline 3.5E+07 3.8E+07 3.1E+07 2.0E+07 1.6E+07 1.8E+07 8.1E+06 0.0E+00 
Leucine/Isoleucine 3.9E+09 3.8E+09 4.0E+09 4.7E+09 3.1E+09 3.9E+09 2.0E+09 3.8E+04 
methyl succinic acid  1.1E+08 1.3E+08 1.0E+08 1.3E+08 1.4E+08 1.4E+08 4.7E+07 2.0E+07 
Asparagine 1.0E+09 1.1E+09 8.8E+08 1.1E+09 1.1E+09 1.1E+09 2.4E+08 1.3E+04 
Hydroxyisocaproic acid 1.8E+09 2.1E+09 1.7E+09 2.1E+09 2.1E+09 2.0E+09 5.5E+07 7.5E+06 
Ornithine 3.3E+08 3.6E+08 2.9E+08 1.5E+08 1.4E+08 1.6E+08 6.7E+06 1.7E+04 
Aspartate 2.7E+09 2.5E+09 2.4E+09 2.1E+09 1.9E+09 2.0E+09 1.0E+09 1.4E+05 
Homocysteine 4.4E+06 3.7E+06 3.1E+06 6.5E+06 6.2E+06 4.1E+06 7.1E+04 0.0E+00 
Anthranilate 9.0E+06 1.0E+07 6.3E+06 5.1E+06 6.6E+06 6.0E+06 2.4E+06 1.7E+05 
Hypoxanthine 1.3E+08 1.3E+08 1.8E+08 2.3E+08 1.1E+08 1.6E+08 1.5E+07 0.0E+00 
Salicylate 3.3E+07 3.7E+07 2.6E+07 2.1E+07 3.2E+07 2.8E+07 7.2E+06 3.9E+06 
Hydroxybenzoate 2.6E+07 2.8E+07 2.2E+07 2.0E+07 2.3E+07 2.2E+07 5.4E+06 3.5E+05 
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Table A-3 Continued. 
COMPOUND 182150_1 182150_2 182150_3 182116_1 182116_2 182116_3 MEDIA BLANK EXTRACTION BLANK 
Acetylphosphate 1.8E+08 1.3E+08 1.5E+08 1.8E+08 1.6E+08 2.2E+08 7.0E+04 3.5E+04 
alpha-Ketoglutarate 4.2E+07 5.2E+07 5.9E+07 1.0E+08 5.0E+07 6.4E+07 2.1E+07 1.0E+06 
Glutamine 2.5E+08 2.7E+08 2.2E+08 2.6E+08 2.8E+08 2.7E+08 1.4E+07 7.1E+03 
Lysine 2.8E+07 2.6E+07 2.6E+07 4.3E+07 3.4E+07 3.4E+07 1.5E+07 0.0E+00 
O-Acetyl-L-serine 1.5E+07 1.8E+07 9.8E+06 2.4E+07 2.7E+07 2.7E+07 2.0E+03 2.4E+03 
Glutamate 3.3E+09 2.9E+09 2.6E+09 2.3E+09 2.0E+09 2.1E+09 6.9E+08 5.5E+03 
Methionine 1.9E+08 1.8E+08 2.4E+08 3.0E+08 1.5E+08 2.1E+08 1.5E+08 0.0E+00 
Guanine 2.3E+07 2.2E+07 2.8E+07 3.7E+07 1.8E+07 2.5E+07 5.4E+06 0.0E+00 
Vanillin 5.0E+08 2.5E+08 1.8E+08 1.5E+08 1.8E+08 1.4E+08 1.3E+08 4.1E+05 
Xylitol 3.0E+06 3.6E+06 3.9E+06 4.3E+06 4.0E+06 3.9E+06 1.6E+07 2.1E+05 
Orotate 1.2E+08 8.8E+07 5.7E+07 2.8E+07 1.9E+07 2.3E+07 1.9E+07 0.0E+00 
Dihydroorotate 4.2E+08 4.4E+08 2.8E+08 9.6E+07 1.3E+08 1.3E+08 6.2E+06 0.0E+00 
pimelic acid 1.9E+07 2.1E+07 1.5E+07 1.4E+07 2.3E+07 1.9E+07 7.2E+06 5.2E+06 
Indole-3-carboxylate 1.2E+06 1.3E+06 1.1E+06 1.1E+06 1.3E+06 1.2E+06 3.8E+05 1.4E+05 
Phenylpyruvate 8.1E+07 7.3E+07 5.4E+07 2.9E+07 5.5E+07 4.8E+07 1.1E+07 7.5E+05 
Methionine sulfoxide 7.1E+06 8.7E+06 1.1E+07 1.6E+07 8.4E+06 1.3E+07 9.6E+06 1.9E+03 
Phenyllactic acid 2.0E+08 2.4E+08 1.7E+08 2.0E+08 2.1E+08 2.0E+08 7.8E+06 9.5E+03 
Cysteate 1.6E+08 1.6E+08 9.8E+07 5.5E+07 9.7E+07 8.7E+07 4.5E+06 1.6E+04 
Sulfolactate 9.3E+07 9.4E+07 2.0E+08 3.4E+08 2.1E+08 2.4E+08 4.4E+07 3.6E+04 
D-Glyceraldehdye 3-phosphate 1.7E+07 2.1E+07 6.5E+07 2.6E+08 2.4E+08 2.2E+08 1.1E+04 0.0E+00 
sn-Glycerol 3-phosphate 3.8E+07 6.5E+07 6.2E+07 8.3E+07 7.6E+07 6.4E+07 4.5E+06 1.2E+04 
Aconitate 9.9E+07 9.2E+07 1.1E+08 2.7E+08 1.6E+08 2.1E+08 3.3E+07 5.2E+06 
N-Acetylornithine 1.8E+08 1.8E+08 1.1E+08 2.2E+08 2.0E+08 2.2E+08 4.6E+07 0.0E+00 
Citrulline 1.8E+09 1.9E+09 1.5E+09 7.5E+08 7.8E+08 8.1E+08 1.0E+07 4.3E+04 
N-Carbamoyl-L-aspartate 1.0E+09 1.0E+09 7.8E+08 2.1E+08 2.1E+08 2.3E+08 1.0E+07 0.0E+00 
Gluconolactone 1.7E+07 1.9E+07 3.1E+07 4.3E+07 1.9E+07 2.8E+07 2.7E+07 5.2E+05 
Hydroxyphenylpyruvate 2.1E+06 1.8E+06 1.6E+06 1.3E+06 1.5E+06 1.4E+06 1.2E+06 6.4E+05 
Tyrosine 4.1E+08 4.3E+08 5.3E+08 6.7E+08 3.4E+08 4.8E+08 3.9E+08 7.5E+03 
Homovanillic acid (HVA) 1.4E+07 1.5E+07 1.1E+07 1.1E+07 9.7E+06 9.9E+06 9.4E+05 3.8E+04 
Homocysteic acid 3.6E+07 3.6E+07 2.1E+07 1.6E+07 2.0E+07 1.9E+07 1.2E+06 4.7E+03 
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3-Phosphoserine 4.4E+06 4.4E+06 4.8E+06 4.3E+06 3.2E+06 3.7E+06 2.0E+06 0.0E+00 
3-Phosphoglycerate 8.1E+08 8.8E+08 8.2E+08 1.0E+09 9.5E+08 9.5E+08 5.8E+05 3.3E+03 
Acetyllysine 9.9E+07 1.3E+08 8.1E+07 1.7E+08 1.6E+08 1.5E+08 6.0E+07 9.0E+02 
N-Acetylglutamate 3.7E+08 4.8E+08 3.3E+08 3.4E+08 2.9E+08 3.2E+08 1.1E+08 3.6E+04 
homocitrulline 3.7E+07 3.4E+07 2.8E+07 2.0E+07 2.2E+07 2.1E+07 2.6E+06 0.0E+00 
D-Gluconate 2.9E+09 3.4E+09 7.1E+09 9.7E+09 9.0E+09 9.2E+09 9.4E+07 2.1E+05 
D-Glucarate 1.4E+06 1.2E+06 3.5E+06 5.5E+06 1.7E+06 3.1E+06 1.1E+06 0.0E+00 
Jasmonate 5.3E+05 5.0E+05 4.6E+05 4.5E+05 5.2E+05 5.1E+05 5.3E+05 3.7E+05 
Deoxyribose phosphate 1.3E+08 1.5E+08 2.4E+08 2.1E+08 1.8E+08 1.7E+08 9.1E+05 0.0E+00 
Cystathionine 5.7E+06 5.7E+06 5.1E+06 2.7E+06 2.9E+06 2.8E+06 3.0E+06 0.0E+00 
deoxycytidine 1.3E+07 1.4E+07 9.7E+06 1.2E+07 9.8E+06 1.0E+07 1.7E+05 0.0E+00 
Ribose phosphate 4.1E+07 5.8E+07 2.2E+08 5.8E+08 4.4E+08 4.5E+08 2.8E+06 0.0E+00 
Uridine 2.5E+07 2.6E+07 2.2E+07 2.2E+07 2.1E+07 2.2E+07 2.8E+06 7.2E+02 
Shikimate-3-phosphate 8.5E+05 5.7E+05 2.3E+06 1.3E+06 1.6E+06 1.5E+06 0.0E+00 0.0E+00 
6-Phospho-D-gluconolactone 2.9E+06 3.0E+06 3.4E+07 6.6E+07 5.6E+07 5.6E+07 0.0E+00 0.0E+00 
Glucosamine phosphate 5.4E+06 8.6E+06 2.5E+07 3.7E+07 3.3E+07 3.1E+07 9.8E+02 0.0E+00 
S-Ribosyl-L-homocysteine 1.5E+07 1.6E+07 1.1E+07 2.2E+07 2.6E+07 2.6E+07 2.9E+05 0.0E+00 
6-Phospho-D-gluconate 1.4E+08 1.3E+08 1.7E+09 2.9E+09 2.5E+09 2.5E+09 9.4E+03 2.3E+03 
Xanthosine 8.3E+06 8.4E+06 8.5E+06 2.9E+06 3.2E+06 3.1E+06 4.7E+06 0.0E+00 
Ophthalmate 1.6E+05 1.6E+05 8.9E+04 9.1E+05 1.2E+05 1.7E+05 1.3E+04 0.0E+00 
Sedoheptulose 1/7-phosphate 2.5E+07 4.3E+07 1.6E+08 2.0E+08 1.5E+08 1.5E+08 4.4E+05 2.7E+03 
N-Acetylglucosamine 1/6-
phosphate 
1.0E+07 1.4E+07 1.5E+07 2.0E+07 1.8E+07 1.9E+07 3.3E+06 0.0E+00 
Glutathione 1.3E+07 1.1E+07 1.1E+07 1.1E+07 6.4E+06 5.2E+06 3.1E+06 0.0E+00 
IMP 1.6E+06 7.9E+05 2.5E+06 1.4E+06 1.4E+06 5.4E+06 7.7E+04 0.0E+00 
Trehalose 6-phosphate 6.6E+05 6.5E+05 1.1E+06 1.4E+06 4.9E+05 8.8E+05 1.9E+06 0.0E+00 
FMN 3.3E+06 3.9E+06 2.4E+06 4.6E+06 5.5E+06 5.0E+06 6.5E+03 0.0E+00 
UDP-glucose 2.5E+08 3.3E+08 3.5E+08 6.2E+08 4.6E+08 4.4E+08 3.1E+04 5.3E+04 
UDP-N-acetylglucosamine 5.1E+07 7.6E+07 4.4E+07 5.0E+07 5.6E+07 4.9E+07 1.8E+06 2.6E+03 
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NAD+ 2.3E+08 2.4E+08 1.7E+08 1.9E+08 2.0E+08 2.0E+08 3.7E+03 0.0E+00 
NADH 5.8E+06 7.2E+06 4.6E+06 5.4E+06 4.9E+06 4.2E+06 0.0E+00 0.0E+00 
Mevalonate 2.4E+07 2.5E+07 2.5E+07 3.0E+07 2.2E+07 2.5E+07 1.0E+07 6.7E+04 
2-C-Methyl-D-erythritol 4-
phosphate 
1.7E+07 1.9E+07 1.3E+07 1.0E+07 1.7E+07 1.1E+07 9.6E+04 2.9E+04 
Isopentenyl diphosphate 1.4E+06 3.5E+06 3.9E+06 1.8E+06 3.5E+06 2.2E+06 9.1E+05 1.7E+05 
Geranyl diphosphate 8.8E+03 2.3E+03 0.0E+00 2.3E+03 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
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